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SOMMARIO 
L'interleuchina-1 beta [IL1β] ed il complesso proteico “inflammasome”, regolatore 
principale della produzione di IL1β sembrano svolgere un ruolo importante nella 
neuroinfiammazione osservata nella malattia di Alzheimer [AD]. L’AD è una 
patologia cerebrale a carattere neurodegenerativo, la cui prevalenza è stimata 
essere in aumento nel corso dei decenni; la caratteristica neuropatologica più 
comune e distintiva è rappresentata dalle placche di beta-amiloide [Aβ] che, con la 
loro deposizione, costituiscono l’elemento chiave per l’innesco di processi 
ossidativi e pro-infiammatori da parte della microglia attivata. L’interazione tra 
microglia attivata e placche di Aβ induce il rilascio di citochine pro-infiammatorie, 
come l’interleuchina-6 [IL6], o di fattori neurotossici, come il tumor necrosis factor-α 
[TNFα]. La produzione di placche amiloidee è dovuta da un lato all’iper-accumulo 
patologico degli oligomeri, dall'altro lato alla ridotta clearance extracellulare degli 
stessi. L'amiloide è fisiologicamente eliminata dal tessuto cerebrale attraverso i 
vasi sanguigni, verso i quali migra nel corso del suo tempo biologico, cioè anni. Il 
risultato è l'accumulo di amiloide dapprima attorno a tali vasi, poi nel tessuto 
cerebrale. L'amiloide insolubile può comportarsi da superantigene, attivando una 
risposta cronica infiammatoria sia umorale che cellulo-mediata. L'infiammazione 
tissutale è dapprima mediata dalla microglia attivata ma, e’ stato dimostrato altresì 
il legame inscindibile tra infiammazione cerebrale e quella periferica. Oltre alla 
microglia, nuovi monociti sono continuamente reclutati dalla periferia verso il 
tessuto nervoso superando la barriera ematoencefalica [BBB] ed una volta arrivati, 
i monociti stimolati assumono il fenotipo macrofagico. La neuroinfiammazione è 
quindi un momento eziopatogenetico fondamentale nella genesi del 
deterioramento cognitivo e della demenza correlate alla patologia di Alzheimer. Sia 
studi post-mortem che su biopsie, tramite immunoistochimica, hanno rivelato la 
presenza di microglia attivata nelle placche amiloidee. Studi immunoistochimici 
inoltre, hanno rivelato la positività per l’IL1, marker di attivazione dell’immunità 
innata mediata da macrofagi e microglia. L'insulto infiammatorio è probabilmente il 
maggior responsabile della perdita neuronale. Ad oggi una diagnosi certa di AD è 
possibile solo mediante analisi post-mortem del tessuto cerebrale: per questo 
motivo negli ultimi anni sono stati ricercati ed individuati degli indicatori biologici ed 
ormonali di malattia, che potessero essere utili nella diagnosi precoce di AD. Tali 
indicatori sono espressi anche dai leucociti periferici, cellule di facile reperibilità che 
rappresentano un’impronta di ció che si verifica a livello di aree cerebrali 
inacessibili in vivo. Alla luce di ciò, i leucociti rappresenterebbero utili elementi per 
studiare le modificazioni che si instaurano a livello cerebrale; pertanto nella prima 
parte del mio progetto, per meglio investigare il possibile coinvolgimento dell’ 
inflammosoma a livello periferico, cellule mononucleate dal sangue periferico 
[PBMC] sono state isolate da individui diagnosticati mediante la scala di 
valutazione Mini-Mental State Examination [MMSE] e classificati come segue: 1] 
individui che presentano cambiamenti lievi ma misurabili nelle capacità di pensiero 
definiti mild cognitive impairment [MCI] [MMSE 24-29]; 2] soggetti con patologia AD 
moderata [MILD] [MMSE 19-24]; 3] individui con patologia AD severa [MMSE <19]. 
Infine sono stati arruolati anche individui sani [HC] di pari sesso ed età come 
gruppo di controllo. PBMC sono stati stimolati con LPS e Aβ [1-42] per valutare l’ 
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espressione dei geni e delle proteine coinvolte nella via dell’ inflammasoma e di 
citochine proinfiammatorie. I risultati ottenuti suggeriscono un coinvolgimento di 
almeno due diversi complessi dell’ inflammosoma nella neuroinfiammazione 
associata alla malattia di Alzheimer. Sulla base di questi risultati, la seconda parte 
del progetto vede come protagoniste cellule di Primary Microglia murina WT e 
knockout per i geni nlrp3 e asc, per completare il quadro di attivazione 
dell’inflammosoma in un contesto di neuroinfiammazione. I dati ottenuti 
confermano il coinvolgimento di NLRP3-inflammasoma nella produzione di 
citochine infiammatorie rendendo questo complesso proteico un potenziale 
bersaglio farmacologico per migliorare la terapia della Malattia di Alzheimer. 
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ABSTRACT  
Interleukin-1 beta [IL1β] and the "inflammasome" protein complex, the main 
regulator of the IL1β production, plays an important role in neuroinflammation 
observed in Alzheimer's disease [AD]. AD is a neurodegenerative disease, whose 
prevalence is estimated to be increasing over the decades; the neuropathological 
characteristic most common are beta-amyloid [Aβ] plaques, whose deposition are 
the key element for the triggering of oxidative and pro-inflammatory processes by 
the activated microglia. The interaction between activated microglia and plaques 
A induces the release of pro-inflammatory cytokines, such as interleukin-6 [IL6], 
or neurotoxic factors, such as tumor necrosis factor-α [TNFα]. The amyloid plaques 
production is due on one hand to the hyper-pathological accumulation of 
oligomers, on the other hand to the reduced extracellular clearance of the same. 
The amyloid is physiologically eliminated from the brain tissue through blood 
vessels, towards which migrates in the course of its biological time [years]. The 
result is the accumulation of Aβ at first around these vessels, and then into the 
brain tissue. The insoluble amyloid can act as superantigen, activating a chronic 
inflammatory response both humoral and cell-mediated activation. The 
inflammation tissue is initially mediated by activated microglia but, it was already 
shown a link between brain inflammation and that device. In addition to microglia, 
new monocytes are constantly recruited from the periphery to the nervous tissue 
overcoming the blood-brain barrier; stimulated monocytes show the same 
macrophage phenotype. Neuroinflammation is therefore a fundamental 
etiopathogenetic moment in the genesis of cognitive impairment and dementia 
related to Alzheimer's disease. Both post-mortem biopsies and 
immunohistochemistry, have revealed the presence of activated microglia in Aβ, 
plaques. Immunohistochemical studies have also revealed positivity for IL-1, 
markers of innate immunity activation mediated by macrophages and microglia. 
The inflammatory insult is probably most responsible for neuronal loss. Currently a 
diagnosis of AD is only possible through post-mortem analysis of the brain tissue, 
which is why in recent years have been researched and identified biological 
indicators and hormonal disease, which could be useful in the early diagnosis of 
AD. These indicators are also expressed by peripheral leukocytes, cells readily 
available, representing a footprint of that which occurs at the level of different brain 
areas in vivo. For this, the white blood cells represent useful elements to study the 
changes that develop in the brain. Therefore, in the second part of the project, to 
better investigate the possible involvement of inflammosome peripherally, 
peripheral blood mononuclear cells [PBMC] were isolated from individuals 
diagnosed with Mini-Mental State Examination [MMSE] and classified as follows: 1] 
individuals with mild but measurable changes in thinking skills defined mild 
cognitive impairment [MCI] [MMSE 24-29]; 2] patients with moderate disease AD 
[mild] [MMSE 19-24]; 3] individuals with severe AD pathology [MMSE <19]. Finally 
they were enrolled even healthy individuals [HC] of equal sex and age as a control 
group. PBMC were stimulated with LPS and Aβ [1-42] to evaluate the 'expression 
of the genes and the proteins involved in the inflammasome pathway and to 
evaluate proinflammatory cytokines production. The results suggest an 
involvement of at least two different inflammasomes-complexes in 
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neuroinflammation associated with Alzheimer's disease. Based on these results, 
the second part of the project aimed at completing the outline of inflammasome 
activation in neuroinflammation context by investigating WT or NLRP3 and Asc 
knockout mouse Primary Microglia cells . Data obtained confirm the NLRP3-
inflammasome involvement in the inflammatory cytokines production making this 
complex a potential drug target for improving the therapy of Alzheimer's Disease. 
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1. INTRODUCTION 
Transcription of pro-IL1β can be induced in monocytes, macrophages and 
dendritic cells upon Toll-Like receptor [TLR] or cytokine signaling [1]. 
Before IL1β can be secreted, it has to be translated and processed into 
mature IL1β by a macromolecular protein complex, the inflammasome. The 
most extensively studied inflammasome is the nucleotide-binding 
oligomerization domain [NOD] like receptor [NLR] family, pyrin domain 
containing 3 [NLRP3] inflammasome [2]. Upon inflammasome activation, 
the NLRP3 protein recruits the inflammasome adaptor protein apoptosis-
associated speck-like protein containing C-terminal caspase recruitment 
domain [ASC], which in turn interacts with pro-caspase-1 leading to its 
cleavage and activation [3]. Finally, the active caspase-1 processes pro-
IL1β into its mature form. A variety of different molecular structures, which 
can trigger inflammasome activation, have been identified, e.g. ATP, 
bacterial toxins or endogenous stimuli [4]. In addition to IL1β, the NLRP3 
inflammasome also processes IL18, which is another pro-inflammatory 
cytokine. Inflammasome activation is crucial for host defense to pathogens, 
but recent studies have clearly identified a role for the inflammasome in the 
pathogenesis of several inflammatory diseases as well [1]. An increased 
NLRP3 inflammasome activity demonstrated by the pro-inflammatory 
cytokines production detected in AD subjects might be important to 
increase the inflammatory process responsible to the neurodegeneration in 
AD’s pathology.  
The role of myeloid immune cells, including microglia, macrophages and 
monocytes, in neural disease remains controversial. It is known as 
chemokine receptors and adhesion molecules are used selectively for the 
transmigration of leukocytes across the blood–brain barrier [BBB] during 
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neuroinflammation. Activated microglia appears to contribute to the 
development of several neurodegenerative disorders, such as Alzheimer's 
disease, but in the literature there are different results regarding PBMC 
infiltration in the CNS as a support to microglia. PBMC were implicated in 
experimental autoimmune encephalitis [EAE], the mouse models of multiple 
sclerosis, as blockage of their infiltration in the CNS ameliorated disease 
development [5,6]. Conversely, inhibition of PBMC infiltration in an 
Alzheimer's mouse model resulted in exacerbation of the disease [7]. 
Recruitment of PBMCs in the brain of an Alzheimer's disease mouse model 
appeared to mediate reduction of plaque formation in the brain. This study 
is among the few conducted on human PBMCs by means of which we 
validated inflammasomes-complex activation with the progression of the 
disease and we evaluated whether inflammation that follows its activation 
may be advantageous or not for AD. 
 
1.1 ALZHEIMER'S DISEASE 
AD, the most common form of dementia, is a degenerative disorder of the 
brain that leads to memory loss [22]. AD affects 5.3 million Americans and 
is the seventh leading cause of death in the United States. There are two 
main forms of the disease. Familial AD affects people younger than 65, 
accounting for nearly 500,000 AD cases in the United States alone. The 
remainder of AD cases occurs in adults aged 65 and older and is classified 
as sporadic AD. The prevalence of AD varies among many different factors, 
including age, co-morbidities, genetics, and education level. Damage to the 
entorhinal cortex, hippocampus and basal forebrain, leading to memory 
impairment, temporal and spatial disorientation and altered cognitive 
function, are pathological features of AD. Two histopathological lesions 
earmarked the disease: extracellular amyloid deposits [chiefly composed of 
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amyloid-β peptides] and intracellular neurofibrillary tangles [NFTs, made up 
primarily of abnormaly folded tau protein]. Over the last hundred years, 
intense focus has been directed toward understanding AD pathoetiology 
and potential treatment approaches aimed to controlling these pathology. 
The lengthening of life expectancy, especially in developed countries, the 
increased incidence of AD, requires a greater investment of financial 
resources. The diagnosis of AD requires a multidisciplinary approach, a 
combination of sensitive and specific diagnostic clinical criteria that allow 
the identification of the disease from the beginnings. Therapies strategies 
are prevent/delay the onset and progression but in several cases of 
dementia make the diagnosis is so difficult. There is no cure for AD, 
however promising research and development for early detection and 
treatment is underway. 
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1.1.1 HISTORY 
Alzheimer’s disease was discovered in 1906 by Alois Alzheimer, a German 
neurologist and psychiatrist. The disease was initially observed in a 51-
year-old woman named Auguste D. Her family brought her to Dr. Alzheimer 
in 1901 after noticing changes in her personality and behavior. The family 
reported problems with memory, difficulty speaking, and impaired 
comprehension. Dr. Alzheimer later described Auguste as having an 
aggressive form of dementia, manifesting in memory, language and 
behavioral deficits [9]. Dr. Alzheimer noted many abnormal symptoms, 
including difficulty with speech, agitation, and confusion. He followed her 
care for five years, until her death in 1906. Following her death, Dr. 
Alzheimer performed an autopsy, during which he found dramatic 
shrinkage of the cerebral cortex, fatty deposits in blood vessels, and 
atrophied brain cells. He discovered neurofibrillary tangles and senile 
plaques, Bethune which has become indicative of AD. The condition was 
first discussed in medical literature in 1907 and named after Alzheimer in 
1910. 
In Alzheimer's disease, the first alterations in the cerebral cortex are found 
primarily in the entorhinal region, located in the anterior portions of the lap 
hippocampus of the temporal lobe [10]; these changes affect subsequently 
other areas of the cerebral cortex and subcortical nuclei of specific groups. 
Macroscopic examination show in AD patient a variable degree of cortical 
atrophy, decrease of the weight and volume of the organ, thinning of the 
layers of the neocortical convolutions in regions involved in the processes 
of memory and learning, as the temporal cortex, parietal, frontal, 
hippocampus and amygdale. Neuronal degeneration involves atrophy, 
which is followed by a compensatory ventricular enlargement, secondary to 
the loss of parenchyma. Normally all macroscopic changes observed in AD 
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patients are also found in healthy elderly subjects and physiological 
expression of brain aging. In Alzheimer's patients it is however 
characterized by their greater quantities and their peculiar distribution. At 
the histological level, it is possible to demonstrate the accumulation of two 
different proteins: the Aβ that is deposited extracellularly, and the protein 
phosphorylated  which constitutes intracellular neurofibrillary tangles . 
The Aβ is organized in different forms, the neuritic plaques [senile plaques], 
constituted by a central compact part of insoluble fibrils of Aβ protein, 
surrounded by an agglomerate with inflammatory degeneration of neurites 
[axons and dendrites], reactive astrocytes and activated microglia 
[monocytes or activated macrophages derived from reticuloendothelial 
system resident in CNS - SNC]; they are located mainly in hippocampus 
and limbic structures, the amygdala, the subiculum and entorhinal cortex. 
The tangles consist of compact bundles of filaments abnormal [paired 
helical filaments], mainly from protein ; they affect mainly the soma, but 
may also extend to the dendrites. These filaments are the cells take a look 
"flame". The "tangles" are mainly located at the level of medium-sized 
pyramidal neurons of the entorhinal cortex, the limbic cortex, hippocampus, 
amygdala, neocortical layers of frontal and temporal lobes and the 
cholinergic system of the basal ganglia [10]. 
1.1.2 GENETICS OF AD 
Alzheimer genetics is traditionally subdivided into early onset [EOAD] and 
late onset [LOAD]. EOAD has an onset before age 60–65 years and 
accounts for 1–5% of all cases. LOAD has an onset after age 60-65 years 
and is the predominant form of AD. Additionally family history may be 
consistent with familial, or sporadic AD [11]. A small number of families 
worldwide have a faulty gene on chromosome 21, the gene for amyloid 
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precursor protein [APP], which affects the production of the amyloid 
peptide. A slightly larger number of families lead to a failure in the gene 
presenilin 1 [PS1], localized on chromosome 14, and a very small number 
of families have a faulty gene presenilin 2 [PS2] in the chromosome 1 [12]. 
People with mutations in either gene tend to develop the disease between 
30 and 40 years old and come from families in which several members also 
have early-onset Alzheimer's, so this form is called familial Alzheimer 
disease [FAD] [Table1]. Sporadic Alzheimer, late onset, is the most 
common form of the disease [Table 1]. The apolipoprotein E [ApoE], the 
effects are more subtle than those of the other genes of early onset and 
even individuals: Currently only one gene can exert great influence on the 
development of sporadic AD it is known two copies of the gene risky way 
not necessarily develop the disease [13]. 
1.1.3 FREQUENCY OF ALZHEIMER DISEASE 
In 2005, Alzheimer Disease International commissioned an international 
group of experts to reach a consensus on dementia prevalence and 
estimated incidence in 14 World Health Organization regions, based on 
epidemiological data acquired over recent years. The results suggested 
that 24.2 million people lived with dementia at that time, with 4.6 million 
new cases arising every year. North America and Western Europe have at 
age 60 the highest prevalence of dementia [6.4 and 5.4% of the population 
at age 60], followed by Latin America [4.9%] and China and its developing 
western-Pacific neighbors [4.0%]. The annual incidence rates [per 1000] for 
these countries were estimated at 10.5 for North America, 8.8 for Western 
Europe, 9.2 for Latin America and 8.0 for China and its developing western-
Pacific neighbors, increasing exponentially with age in all countries, 
especially through the seventh and eighth decades of life [14]. The 
prevalence rates for AD also rise exponentially with age, increasing 
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markedly after 65 years. There is almost a 15-fold increase in the 
prevalence of dementia, predominately Alzheimer disease, between the 
ages of 60 and 85 years. Compared with Africa, Asia and Europe, the 
prevalence of AD appears to be much higher in the US, which may relate to 
methods of ascertainment. The prevalence may be higher among African-
American and Hispanic populations living in the US, but lower for Africans 
in their homelands, for reasons that remain uncertain [15].  
1.2 RISK FACTORS THAT INCREASE ALZHEIMER’S DISEASE 
The numerous risk factors identified to date, although not systematically 
confirmed, suggest that AD is a multifactorial etiology. The most important 
are describer in Table 2.  
1.2.1 DIAGNOSTIC CRITERIA 
Currently, the diagnosis of dementia is made according to the clinical 
criteria of Diagnostic and Statistical Manual Mental Disorders [DSM IV TR] 
published by American Psychiatric Association [APA]. Instead, in 1984, 
representatives from the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer Disease and 
Related Disorders Association [NINCDS-ADRDA] developed a uniform set 
of criteria to enable clinicians and researchers to maintain consistency in 
the diagnosis and differentiation of the different types of dementia. 
According to these criteria, the clinical AD diagnosis is defined probable in 
the presence of cognitive impairment confirmed by neuropsychological 
tests. The definitive diagnosis is possible only through histopathology brain.  
Furthermore, research has made available biomarkers in serum and CSF, 
thorough  genetic investigations and advanced neuroimaging techniques. In 
2007, Dubois et al [16] have proposed a revision of the NINCDS-ADRDA, 
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suggesting integration of the clinical features of the disease  [the presence 
of the disorder of memory] with the biological parameters in serum 
[mutations of APP, presenilin 1 and 2, ApoE ε4 allele] and CSF [β-
amiloide1-42, tau protein] and structural neuroimaging data [atrophy of the 
medial temporal lobe structures detected with techniques Magnetic 
Resonance Imaging [MRI] and functional [alterations of cerebral 
metabolism detected with Positron Emission Tomography [PET]. All these 
factors would increase the specificity and sensitivity of AD diagnostic  
criteria and would identify individuals with at earlier stages of disease. The 
medical case is obtained by the assessment of the state of mind, made by 
administering cognitive tests, such as the Mini Mental State Examination 
[MMSE] [17] and neuropsychological testing, and by the assessment of 
functional independence of the subject, through the use of scales that 
assess basic activities instrumental of daily living, such as ADL [Activities of 
Daily Living, Katz index] [18] and IADL [Instrumental Activities of Daily 
Living, Lawton index] [19]. Aspects regarding the clinical features are then 
integrated with the structural and functional neuroimaging and the study of 
genetic and biochemical markers. As already mentioned above, there are 
three main categories of biomarkers currently identified for the diagnosis of 
Alzheimer's disease: genetic, biochemical and neuroimaging [Table3]. 
1.2.2 ETHIOLOGY 
AD etiology is still unknown; currently accepted theory is the amyloid 
hypothesis which is supported by the observation of plaques containing this 
molecule in AD brain . However, the presence of amyloid plaques alone 
can not justify the onset of AD; amyloid plaques are developed in the brain 
tissue of elderly subjects, even cognitively intact, suggesting that the 
deposition of plaques is actually a paraphysiological phenomenon and the 
discriminating factors for the onset of AD may be the place where they are 
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deposited, as well as interaction with other co-factors, equally important for 
the development of the disease. Many of these have been extensively 
studied, in order to better define their role in the etiopathogenesis of AD; at 
present, the most important co-factors involved appear to be 
hyperphosphorylated  protein, ApoE and other inflammatory mediators 
[20] [Figure1]. 
1.3 THE AMYLOID HYPHOTESIS 
Senile plaques in AD brain contain Aβ, a peptide of 40-42 amino acids, 
derived from a larger precursor, APP [amyloid precursor protein] by a 
proteolytic process [35]. The APP is an integral transmembrane protein 
present in several isoforms, all encoded by a single gene located on human 
chromosome 21. 
The APP is expressed in the CNS, but it is also ubiquitously expressed in 
different variations in peripheral tissues, such as muscle cells, epithelial 
and circulating cells (especially platelets) [21]. It has functions of adhesion 
to extracellular matrix receptors [average specific intracellular mechanisms] 
and modulation of gene expression. In addition, molecules secreted APP in 
forming synapses and probably play a role in the integrity of the mnemonic 
process. This protein has a massive N-terminal portion [4/5 of the total 
weight of the molecule], and a C-terminal portion of approximately 100 
amino acids that constitutes the intracytoplasmic domain of the protein. In 
proximity to the C-terminal an amino acid sequence, referred to as Aβ, acts 
at the level of the three main enzymes involved in the metabolism of APP: 
α-secretase, β-secretase and γ-secretase. In relation to the activity of 
these enzymes, the APP can follow two different routes of processing 
[Figure2] [22]. 
No-amyloidogenic process is provided by dell'α- secretase [ADAM10], 
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which cleaves APP at residue 16 of the Aβsequence and gives rise to a 
large fragment soluble N-terminal 83 aminoacids, called sAPPα, that is 
released into the circulation, and to another fragment of 83 aminoacids, at 
the level of the end C-terminal [CTF83], which remains attached to the cell 
membrane where, will encounter cleavage by the γ-secretase. The 
amyloidogenic pathway involves the action of β-secretase [BACE] and then 
a second cut by γ-secretase, with release of the Aβ peptide. The β-
secretase performs the cleavage at the level of N-terminus of the Aβ 
sequence, releasing into the extracellular space a soluble fragment, called 
sAPPβ, and leaving attached to the cell membrane a C-terminal fragment 
of 99 amino acids [CTF99], which is then cleaved by γ-secretase exactly at 
the level of the remaining 40 or 42 of CTF99 [22]. Therefore, β and γ-
secretase action results in the release of amyloidogenic Aβ fragments of 40 
and 42 amino acids in the extracellular space, where they can accumulate; 
the Aβ-40 is the form most produced, while Aβ-42 is the main component of 
senile plaques since it has a high potential fibrillogenic and neurotoxic [23]. 
Aβ40-42 fragments spontaneously aggregate to form a β-sheets structure 
which is toxic for neurons and synapses, both in its early form [monomeric, 
dimeric or oligomeric], both as deposit in aggregates, the senile plaques. It 
is believed that the toxic effects of Aβ can cause the development of 
dementia [24]. In healthy individuals the two ways of processing of APP are 
in balance with each other, while it is believed that in the individuals with 
Alzheimer's disease there is a state of imbalance, with respect to the 
prevalence of the amyloidogenic pathway via non amyloidogenic.  
1.4 EVOLUTION OF THE DISEASE 
The disease, as suggested by Braak and Braak [1995], evolves in a 
sequence of time and space through the structures of the medial temporal 
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cortex, subcortical nuclei and neocortical areas of the brain. It can be 
recognized six phases. In stage transentorinale [stages I and II], the signs 
of the disease are confined mainly to the entorhinal cortex and 
transentorinale, with lack of involvement of the hippocampus sections CA1 
and CA2. The stadium limbic [stages III and IV] is characterized by the 
presence of neurofibrillary lesions in the entorhinal cortex, hippocampus 
moderates from tangles and their increasing use to amygdala, the thalamus 
and the hypothalamus. Finally, the neocortical stage [stage V and VI] is 
characterized by the progressive involvement of the neocortex [Figure3]. 
The clinical characterization suggested that the stadium transentorinale is 
the preclinical and asymptomatic period of the disease, while the stadium 
limbic represents the incipient stage of the disease characterized by the 
appearance of the first clinical symptoms. The stadium neocortical is 
characterized by the full-blown disease [25] The transition from one stage 
to another is gradual and sequential. Recent reports suggest that the 
presence of neurofibrillary tangles inside neurons does not necessarily 
mean the immediate cessation of cell function, but that these neurons can 
stay alive for many years after their appearance [26,27]. 
1.4.1 CLINICAL EVOLUTION 
The diagnosis of the disease and identification of its various stages of 
evolution is possible only using different evaluation criteria: tests to assess 
the cognitive condition of the patient, detailed clinical observations, 
interviews to the patient and a through family history. However no test pre-
mortem is able to perform a certain clinical diagnosis of Alzheimer's 
disease. So, for every clinical diagnosis must follow a "post-mortem 
analysis”. This means that during the course of the disease can only be 
done a diagnosis of Alzheimer's "possible" or "probable". In fact only the 
autopsy can give confirmation of the presence of typical lesions typical of 
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the disease. Currently, the term most used to describe the preclinical phase 
of dementia is Mild cognitive impairment [MCI]. People with MCI have 
memory loss greater than that which would be expected for the age, but 
they have a cognitive and functional impairment that they can be diagnosed 
as dementia. The most accepted diagnostic criteria for MCI are those 
proposed by [28]: a] subjective annoyance memory preferably confirmed by 
a person other than the individual; b] the presence of a memory deficits 
documented by a service in a test of episodic memory; c] absence of other 
cognitive deficits; d] normal abilities in activities of daily living; e] absence of 
dementia [Figure4]. From a review of major studies on the rate of 
conversion from MCI to dementia [29] it follows that in subjects with MCI 
this rate varies between 6 and 25% and is much higher than that observed 
in normal elderly subjects, where it ranges between 0.3% in individuals 
between 65 and 69 years and 5.3% in individuals between 85 and 89 
years. 
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1.5 ALZHEIMER AND INFLAMMATION 
The inflammatory reaction which characterizes the majority of 
neurodegenerative disorders, including AD, is often called 
"neuroinflammation" and involves mainly components of innate immunity. 
Microglial cells, the primary immune effector cells of the brain, play an 
integral role in maintaining brain homeostasis and protecting the brain from 
infections and insults. In the AD brain, microglial cells are observed to be 
phenotypically activated and form intimate associations with amyloid 
deposits, extending their processes into the plaque core [30,31]. Microglia 
are able to recognize and mount an immune response to Aβ peptides as 
well as migrate to areas of amyloid deposition, however, despite their ability 
to physically interact with these deposits they are unable to clear plaques 
from the brain. The role of microglia in the uptake and phagocytosis of 
amyloid in the brain was first noted in the early 90’s by Wisniewski and 
Frackowiak who utilized electron microscopy to visualize amyloid 
internalization [32,33]. They postulated that resident microglial cells 
associated with plaques in the AD brain played a role in the formation of the 
amyloid fibrils in the brain, but not its phagocytosis [46]. However, in rare 
cases in which AD patients suffered from stroke they were able to visualize 
macrophages that had internalized and trafficked amyloid deposits into 
lysosomal compartments [34]. This is the first study that hypothesized that 
peripherally- derived myeloid cells were more competent than endogenous 
microglia in the clearance of amyloid in the brain. The deposition of amyloid 
in the parenchyma of the brain is associated with a robust inflammatory 
response [35]. It is thought that this chronic pro-inflammatory milieu 
produced by “activated” microglia is neurotoxic and facilitates 
neurodegeneration. It is now understood that the inflammatory response in 
AD is multifaceted with the role of microglia in disease progression being 
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both complex and quite controversial. The paradox over whether they play 
a neuroprotective role in the AD brain or facilitate and contribute to the 
neurotoxicity observed in AD is a puzzle that is currently under active 
investigation. 
An extensive literature documents that inflammation plays an integral role 
in progression of AD, facilitating Aβ deposition, neuronal loss and cognitive 
deficits [36]. The appearance of amyloid plaques in the brain coincides with 
a dramatic phenotypic activation of the surrounding microglia which display 
increased immunoreactivity for CD11b, CD68, complement receptor 3 and 
CD45 [37]. Amyloid and activated microglia secreting cytokines usually 
precedes changes in neurodegenerative AD. Moreover, the polymorphisms 
present in the genes of some cytokines [IL1β, IL6, TNFα] and acute phase 
proteins [α1-antichymotrypsin] are associated with an increased risk of AD 
[38]. Accumulation of Aβ may be initially determined by defects in 
physiological mechanisms of its clearance and degradation in the brain. Aβ 
clearance physiological could happen thanks to the drainage to the 
perivascular spaces, or actively through the uptake and processing of the 
same by the astrocytes, the microglia or macrophages derived from 
monocytes: the latter would seem the only ones able to access deposits of 
fibrillar Aβ [39]. Currently, there is therefore a uniform consensus in 
accepting inflammation as key feature in the pathogenesis of AD [39,40]. 
Another demonstration of an activation of inflammatory processes in the 
early stages of disease would support the hypothesis of inflammation as 
the "prime mover", although the inflammation could play a key role in the 
etiopathogenesis of the disease.  
The SNC can no longer be considered an organ isolated and protected 
from the action of the immune system. It is now known that T cells are able 
to cross the blood brain barrier [BBB] and to release mediators of 
inflammation in the course of neurodegenerative diseases. In addition, the 
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microglia expresses different molecules involved in the immune response 
including major histocompatibility antigens of type I and II that facilitate 
interaction with T lymphocytes, which, in turn, determine the production of 
inflammatory cytokines [41,42]. The plaques of Aβ induce the proliferation 
of astrocytes, which are also glial cells, which would participate in the Aβ 
clearance and degradation forming a protective barrier between the 
deposits of Aβ and neurons. However, the presence of activated astrocytes 
might also be justified for the neurotrophic activity of the substances 
produced. The neurons themselves, reacting to stimuli toxic, may directly 
contribute to the maintenance of the inflammatory response: traditionally 
believed as passive targets of inflammation, recent evidence suggests that 
they themselves are the source of complement factors and cytokines 
including IL1β, IL6 and TNFα. 
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1.6 INNATE IMMUNE RESPONCE IN ALZHEIMER’S DISEASE 
1.6.1 MONOCYTE 
Monocytes constitute a population of circulating leukocytes that are central 
cells of the innate immune system. They are part of the mononuclear 
phagocyte system that arises from the hematopoietic system, which is 
constituted by self-renewal hematopoietic stem cells and progenitor cells 
located in the bone marrow [BM] [43]. Monocytes come from the 
monocyte–macrophage dendritic cell progenitor and are incompletely 
differentiated cells that give rise to a heterogeneous mononuclear 
phagocyte lineage [56]. They express multiple clusters of differentiation 
[CD], namely CD115, CD11c, CD14 and CD16 in human or CD115, CD11b 
and Ly6C in mouse [44]. In parallel, both human and murine monocytes 
express different levels of chemokine receptors, among which are 
chemokine [C-X3-C motif] receptor 1 [CX3CR1] and chemokine [C-C motif] 
receptor 2 [CCR2] [45]. In human, monocytes are regrouped into three 
main subsets based on their CD14 and CD16 expression levels, which are 
the classical subset [CD14++CD16−], the intermediate subset 
[CD14++CD16+] and the nonclassical subset [CD14+CD16++] [46]. 
Monocytes are very potent phagocytic cells that respond to stress signals 
by expressing a variety of surface molecules, among which are scavenger 
receptors [for example, scavenger receptor SR-A, CD36], low-density 
lipoprotein receptors [for example, low-density lipoprotein receptor-related 
protein, LRP1], toll-like receptors [for example, TLR2, TLR4], chemokine 
receptors [for example, CCR2, CX3CR1], cytokine receptors [for example, 
macrophage colony-stimulating factor [M-CSF] receptor], Fcγ receptors and 
adhesion molecules [for example, leukocyte function-associated antigen, 
LFA-1], wherein the expression level of these molecules reflects their 
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respective functions [44]. Monocytes are involved in innate immunity by 
defending the organism against pathogens and toxins [44]. Little is known 
about monocyte interaction with the brain under physiological conditions. 
However, it has been proposed that circulating monocytes more precisely, 
the patrolling subset that has a long half-life [45] replenish the perivascular 
macrophage population in normal tissue, which is involved in maintenance 
of homeostasis of the perivascular space [45]. Under pathophysiological 
conditions, short-lived circulating proinflammatory monocytes are mobilized 
from the BM to the blood circulation in a CCR2-dependent manner [46,47]. 
These cells have been shown to possess the capacity to infiltrate inflamed 
tissues of several organs, including the brain [45]. The infiltration rate of 
monocytes increases in response to brain-derived inflammatory cues [37]. 
Following injured brain infiltration, monocytes can differentiate into 
activated macrophages that are involved in the production of various 
inflammatory molecules, such as IL1β and TNFα [44], and phagocytosis of 
toxic elements, including Aβ [48]. It is noteworthy to mention that 
morphologically these monocyte-derived macrophages are 
indistinguishable from brain resident microglial cells, but functionally they 
show a more efficacious phagocytic capacity [48]. The infiltration of 
monocyte subsets in the inflamed brain and their differentiation into 
macrophages totally depend on the inflammatory cues present within their 
microenvironment. Circulating monocytes are able to infiltrate the brain in 
AD. BM-derived macrophages, which originate essentially from infiltrated 
proinflammatory monocytes, have been shown to be more efficacious than 
resident microglia in clearing cerebral Aβ deposits in AD models [49].  
1.6.2 MICROGLIA 
Microglia are the resident macrophages of the brain, and constitute the 
main active immune cells in the brain. Although the origin of microglia is still 
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elusive, it is well accepted that these cells arise from myeloid precursors 
and constitute an ontogenically distinct population of mononuclear 
phagocytes [50]. As such, microglial cells arise from hematopoietic 
progenitors in the yolk sac during embryogenesis and are generated in the 
postnatal stage just after the formation of the BBB [51]. Microglia survey the 
brain and are actively involved in maintaining the brain’s microenvironment 
by rapidly responding to pathogens and/or damage [Figure 4] [52,57]. 
Moreover, microglial cells adopt a special phenotype and cellular 
morphology that is characterized by high ramifications that constitute 
dynamic and motile sentinels, by which microglia sense any occurring 
change in their close microenvironment [47,53]. Under physiological 
conditions, recent reports show that microglia actively contribute to 
neuronal plasticity and circuit function [54].  
Under pathophysiological conditions, microglial cells are activated and 
acquire a new morphology characterized by an amoeboid shape. Activated 
microglial cells are capable of performing several macrophage-like immune 
functions, such as cytokine release and phagocytosis [52,53]. In parallel 
with the newly acquired morphological shape, activated microglia 
upregulate several key surface markers involved in phagocytosis. Once 
activated, microglia can adopt diverse phenotypes ranging between two 
extremes: a classically activated M1 phenotype that is involved in 
proinflammatory actions, and an alternatively activated M2 phenotype that 
is mainly involved in anti-inflammatory actions and tissue repair [51]. The 
molecular cues present within the microglial microenvironment play a 
crucial role in mediating their activation phenotype. It is important to 
mention that, in the diseased brain tissue, both extremes cohabit within a 
spectrum of different intermediate phenotypes. 
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1.7 PATHOGEN RECOGNITION RECEPTORS [PRRS] 
The immune response is divided into innate and adaptive. Innate immunity 
is by definition universal, rapid, highly conserved and present from birth; it 
is usually the first form of defense against an external insult. The adaptive 
immune response is highly specific and develops much more slowly upon 
exposure to toxins or pathogens. The innate immune response is involved 
in various inflammatory processes and has a particularly important role in 
the initial and final phases of bacterial and viral infections. Effectors of the 
innate immune system, the PRRs are activated immediately after exposure 
to infectious agents, limiting later replication. The PRRs are expressed by 
different cell types including macrophages, monocytes, dendritic cells, 
neutrophils, epithelial cells and, in general, in all cells of the adaptive 
immune response. The PRRs include membrane receptors Toll-like 
Receptors [TLRs] and C-type lectins [CTLs] that "control" the presence of 
PAMPs [pathogen-associated molecular patterns] extracellular and 
endosomal compartments [55,56]. The signal transduction of these 
receptors converges on a common set of signal modulators which often 
include the activation of the transcription factor NF-kB [nuclear factor 
kappa-light-chain-enhancer of activated B cells] and AP-1 [activator protein-
1] that drive the production of pro-inflammatory cytokines, chemokines and 
the members of the family of transcription factors that mediate the response 
of IRF dependent antiviral interferon type 1 [IFN-dependent]. Another group 
of receptors are those intracellular PRRs denominated NOD-like receptors 
[NLRs] that recognize and bind to other molecules called PAMPs and 
danger-associated molecular patterns [DAMPs] [1]. 
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1.7.1 TLR RECEPTORS: STRUCTURE AND LIGANDS  
TLRs are divided into two subgroups depending on their cellular localization 
and their ligand [PAMP]. A group is composed of TLR1, TLR2, TLR4, 
TLR5, TLR6 and TLR11, expressed on the cell surface that recognize and 
bind to different substrates such as microbial lipids, lipoproteins and 
proteins; the other group includes TLR3, TLR7, TLR8 and TLR9, expressed 
exclusively in intracellular vesicles such as the endoplasmic reticulum [ER], 
endosomes, and lysosomes which recognize and bind to microbial nucleic 
acids. The TLRs have a transmembrane domain which binds an 
extracellular domain rich in leucine and an intracellular cytoplasmic domain 
[TIR]. The TLR4, one of the most studied and known TLR, has been 
identified as the receptor for the lipopolysaccharide [LPS], a component of 
the cell membrane of Gram-negative bacteria. TLR4 was the first TLR to be 
identified and whose property was crystallized making possible the 
computational simulation of the model that predicts the mechanism of 
interaction with the ligand [57]. The TLR4 forms a complex with myeloid 
differentiation factor 2 [MD2] on the cell surface, allowing the link with LPS. 
A structural study of the TLR4-MD2 complex with LPS showed that five or 
six lipid chains of LPS bind the hydrophobic part of MD2 and that the 
remaining lipid chains are associated with TLR4 [57,58]. The ligand binding 
to TLR4, leads to activation of the complex TLR-4/MD2 which culminates 
with the production of pro-inflammatory pathway through the myeloid 
differentiation primary response protein 88 [MyD88] employee, and with the 
production of interferon Type-1 through MyD88 independent pathway 
[Figure 7]. The MyD88-dependent signaling recruits IRAK1 [IL-1R-
associated kinase] and IRAK4, and TRAF6 [TNF [tumor necrosis factor] -
receptor-associated factor 6] making active the transcription factor NF-kB 
through dissociation of its inhibitor IkB. This process culminates with the 
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translocation of NF-kB in the nucleus and the subsequent activation of the 
transcription of immunoregulatory genes [59,60]. 
 
1.8 NOD-LIKE RECEPTORS [NLRS] AND INFLAMMASOMES 
The NLRs are intracellular receptors belonging to the family of PRRs that 
recognize PAMPs and DAMPs. The family of NLRs is characterized the 
presence of a central domain [NACHT] which bind at the C-terminal 
leucine-rich repeats [LRRs] and N-terminal caspase recruitment domain 
[CARD]. The domain NACHT is the only common to all members of the 
family of NLRs [Figure 8]. NLR receptor forms a complex with the effector 
molecule, pro-caspase-1, with or without the help of an adapter molecule 
such as apoptosis-associated speck-CARD domain [ASC]. The complex so 
formed is called the "inflammasome" [Figure 9].  
The concept of inflammasome was introduced for the first time by Tschopp 
and collaborators in 2002 that described it as a multiprotein complex 
capable, following an inflammatory insult, to control the production of pro-
inflammatory cytokines important such as IL1β and IL18 [1]. IL1β is 
synthesized as an inactive precursor [pro-IL1β] in response to TLR ligands 
such as LPS. The crucial signal transduced by TLRs for the induction of 
pro-IL1β expression is likely activation of the transcription factor NF-kB 
downstream of the adapter MyD88. The cytokine IL18 shares many of the 
pro-inflammatory characteristics of IL1β and it is synthesized too as an 
inactive precursor [61  ]. Unlike pro-IL1β, however, pro-IL18 is expressed 
constitutively. Biologically active IL1β and IL-18 are generated from pro-
IL1β and pro-IL18 by the aspartate-specific cysteine protease, IL1β-
converting enzyme [ICE] e also known as caspase-1. The mechanism by 
which IL1β is secreted from the cell remains unclear. Pro-IL1β lacks a 
signal peptide and has a diffuse distribution in the cytoplasm. Caspase-1 
22 
 
itself is synthesized as an inactive 45-kDa zymogen [pro-caspase-1] that 
undergoes autocatalytic processing upon receipt of an appropriate 
stimulus. The active form of the enzyme comprises the subunits, p20 and 
p10, which assemble into a heterotetramer [61]. Although caspase-1 was 
the first mammalian caspase to be identified, how PRRs promote caspase-
1 activation and subsequent processing of pro-IL1β remained elusive for 
many years. Activation of caspase-8 by death receptors and caspase-9 by 
Cytochrome c released from mitochondria had been shown to involve pro-
caspase recruitment to the oligomerized adapters FADD and Apaf1, 
respectively. Tschopp and colleagues investigated whether caspase-1 also 
was activated within a multiple adapter complex. In vitro setting, they 
observed the formation of a complex composed of the intracellular 
adapters: ASC and NALP1 together with caspases-1 and 5. Like caspase-
1, ASC and NALP1 contain a CARD domain [62]. 
In ASC-dependent inflammasomes, upstream sensor proteins, such as 
NLRP3 and AIM2, recruit ASC via interactions between their PYDs. ASC 
then interacts with caspase-1 via CARD/CARD interactions. Therefore, the 
bipartite nature of ASC represents the core structure of these 
inflammasomes. The NAIP/NLRC4/caspase 1 complex is a representative 
ASC-independent inflammasome, [Figure 10] in which NAIP is the sensor 
and NLRC4 is the adaptor, although both NAIP and NLRC4 belong to NLRs 
by domain definition . NLRC4 contains a CARD and can directly recruit and 
activate caspase-1 [62].  
1.8.1 NLRP3-INFLAMMASOME 
NLRP3 inflammasome was the first to be described by Hoffman. More 
recently Agostini et al. [63] demonstrated NLRP3-inflammasome ability to 
process the pro-IL-1β. The NLRP3 inflammasome is the most studied and 
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best characterized; is formed by the NOD-like receptor, the adapter 
molecule ASC and the effector molecule, pro-caspase 1. It is now generally 
accepted that activation and release of IL-1β requires two distinct signals. 
The first signal is triggered by TLR activation and leads to the synthesis of 
pro-IL-1β and other proteins required for inflammasome. The second signal 
that is required for caspase-1 activation and IL-1β secretion [64]. 
Signal 1: priming 
Multiple signals, which are potentially provided in combination, can trigger 
the formation of an active inflammasome, which, in turn, leads to the 
cleavage and release of bioactive cytokines including IL-1β and IL-18. In 
general, priming stimuli can include any whose receptor signaling results in 
the activation of the transcription factor NF-κB, such as ligands for IL-1R1, 
TLRs, NLRs, and the cytokine receptors TNFR1 and TNFR2. The activation 
of NF-κB is critical for upregulating the transcription of both pro-IL-1β and 
NLRP3, as pro-IL-1β is not constitutively expressed and basal levels of 
NLRP3 are inadequate for efficient inflammasome formation. In contrast, 
transcriptional modulation is not required to license the inflammasome 
components, ASC and procaspase-1 [65].  
Signal 2: activation 
The second step in activation of the NLRP3 inflammasome is provided by 
one of a diverse group of agonists that triggers the specific activation of 
NLRP3, assembly of the inflammasome complex, and finally culminates in 
the activation of caspase-1. The activators include both exogenous and 
endogenous molecules such as crystalline molecules, that require 
phagocytosis for activation, ATP acting through its cell surface receptor 
P2X7R, lysosome-derived molecules and reactive oxygen species [ROS] 
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and pore-forming toxins such as nigericin [65] [Figure 11]. 
Recent results show, also, the NLRP3 inflammasome activation in the 
microglia by Aβ-triggers neuroinflammation [66,67] [Figure 11]. Within a 
short period of activation of the innate immune system, the acute 
inflammatory response is started by immune cells enabling secretion of 
various cytokines and chemokines in order to recruit immune cells to the 
site of infection. Neutrophils are the first to adhere to endothelial cells, and 
they begin to migrate across the vascular wall at the site of infection to 
engulf the invading pathogens and also secrete vasoactive and pro-
inflammatory mediators [68]. Most of the early vascular changes observed 
in acute inflammation are due to inflammatory mediators that are released 
by inflammatory cells at the site of injury. These mediators, including 
histamine, platelet-activating factors [PAFs], bradykinin, and thrombin, 
increases vascular permeability followed by fluid accumulation [edema] and 
leukocyte extravasation. However, if the innate immune system exceeds its 
capacity or its defensive function becomes limited, it engages the adaptive 
immune system, activating specific T and B cells for pathogen clearance 
[69]. If this process is prolonged or inefficient, it progresses to the chronic 
state of inflammation that is associated with many diseases such as AD, 
Multiple Sclerosis, Chron’s Disease. 
1.8.2 NLRP1-INFLAMMASOME 
NLRP1 was the first inflammasome to be characterized; however, studies 
of this inflammasome have been hampered by issues such as the 
uncertainty as to the identity of a specific ligand, the complexity of its 
domain structure, possible enzymatic modification and the substantial 
divergence between human and mouse NLRP1. Human NLRP1 is unique 
among inflammasome-forming NLRs as it possesses two protein–protein 
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interaction domains: an N-terminal PYD and a C-terminal CARD. Although 
ASC is not part of this inflammasome, it might enhance NLRP1 activation. 
Mice have three Nlrp1 genes [Nlrp1a, Nlrp1b and Nlrp1c]. Instead of a 
PYD, murine NLRP1 proteins have a unique N-terminal domain for which 
there is no known homologue in humans. A distinct feature of NLRP1 in 
both humans and mice is the presence of a function-to-find domain [FIIND] 
at the C-terminal end. The activation of human NLRP1 seems to require 
auto-proteolysis at the FIIND. Interestingly, a naturally occurring splice 
variant of human NLRP1 fails to undergo auto-proteolysis at the FIIND 
region, which prevents subsequent maturation of IL-1β, whereas a single-
nucleotide polymorphism [SNP] that alters this region enhances processing 
and activation of NLRP1 [1]. 
1.9 PERIPHERAL IMMUNE RESPONSE 
Apart from brain-specific changes, abnormalities attributed to AD seen in 
many peripheral cell types such as erythrocytes, lymphocytes, platelets and 
fibroblasts [84,85,86] have led to the speculation that AD might be a 
systemic disorder, with the most prominent pathology in the cognitive 
functions of the central nervous system [CNS]. Indeed, a substantial body 
of data exists indicating that biochemical changes of brain cells in various 
neurobiological diseases with systemic manifestation are reflected in 
peripheral tissues, such as fibroblasts and leukocytes [70,71]. In the course 
of surveying a wide variety of these mirror changes, previous reports have 
proved that fibroblasts and lymphocytes can serve as models and 
diagnostic markers of several neurodegenerative disorders [71,72,73]. 
These peripheral tissues actually offer many advantages for the study of 
various patho-biochemical alterations in AD. One of the main risk factors in 
AD is age, and aging itself is a phenomenon which causes changes in the 
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immune system and in inflammatory parameters [74]. The term 
“inflammaging” characterizes a widely accepted paradigm that aging is 
accompanied by a low-grade chronic up-regulation of certain pro-
inflammatory responses. This systemic immune alteration is evidenced by 
increased serum levels of pro-inflammatory cytokines, including IL-1β and 
TNFα, and other inflammatory biomarkers, such as coagulation factors [75]. 
This abnormal inflammatory state is thought to predispose older adults to 
several neuro-psychiatric disorders, including depression, Parkinson's 
disease [PD] and AD [92,93,94]. Aβ itself has the ability to alter the 
production of pro-inflammatory cytokines [95,96]; in turn, IL1β, particularly 
in combination with interferon [IFN]-γ, induces an over-expression of 
amyloid-precursor-protein [APP], with subsequent accumulation and 
aggregation of Aβ [79,80]. 
About 500 ml of cerebrospinal fluid are taken up every day in the blood and 
numerous evidence suggests that dysfunction of the BBB, typical of several 
neurodegenerative diseases that may affect the exchange between fluids 
protein [81]. As result, the spread of the metabolites present in the CSF, the 
peripheral system could reflect a neurodegeneration. In fact, changes were 
seen at the level of peripheral cells such as PBMCs [Peripheral Blood 
Mononuclear Cells] in patients with AD [99] and with dementia from multiple 
heart attacks [100]. Identifying the biochemical changes in the blood 
components of patients might allow to identify the "fingerprints" devices that 
reflect degenerative processes in the CNS [82].  
As already mentioned, inflammation plays an important role in AD 
pathology and T cells frequently fall and accumulate in the Alzheimer brain. 
However, T cells may not need to infiltrate the brain to exert its effects 
[102]. In humans, native T cells typically express CD45RA ectopically. 
However, when these cells are in the context of antigen stimulation, 
become activated and then go into a resting phase, a change occurs in RA 
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isoform of CD45 RO [84]. This change of isoform can be taken as a marker 
of human memory T cell. Memory T cell is an important phenomenon 
because it allows a much faster response to reconnect with the native 
antigen cell that responds to it first. It has been shown that peripheral T 
cells in patients with Alzheimer present CD45RA change to RO isoform [85] 
and reduction in ectopic expression of receptors for IFNγ [86,87]. It is also 
difficult to understand how peripheral T cells may exert their effects without 
infiltrating the CNS. One possibility is that these activation could lead the 
secretion of cytokines such as IFNγ, and these proinflammatory cytokines 
enter the CNS and activate microglial and/or astrocytes. In another 
scenario, activated peripheral T cells can promote activation of myeloid 
cells such as monocytes, macrophages and/or dendritic cells that secrete 
proinflammatory cytokines such as TNFα, IL1β and IL6. Thus, there is 
evidence of elevated levels of IL6 in monocytes from patients with 
Alzheimer's [88]. These cytokines can promote brain inflammation and 
gliosis, once they have crossed the blood-brain barrier, and can exacerbate 
the inflammatory responses of the brain to amyloid plaques [89]. 
28 
 
AIM 
There is extensive evidence that accumulation of mononuclear phagocytes 
including microglial cells, monocytes, and macrophages at sites of β-
amyloid deposition in the brain is an important pathological feature of 
Alzheimer’s disease [AD] and related animal models, and the concentration 
of these cells clustered around Aβ deposits is several folds higher than in 
neighbouring areas of the brain [90-94]. Microglial cells phagocyte 
pathogens and toxins, but they can also be activated to produce 
inflammatory cytokines, chemokines, and neurotoxins [95]. Over the past 
decade, the roles of microglial cells in AD have begun to be clarified, and 
was proposed that these cells play a dichotomous role in the pathogenesis 
of AD [93, 95–100]. Microglial cells are able to clear soluble and fibrillar Aβ, 
but continued interactions of these cells with Aβ can lead to an 
inflammatory response resulting in neurotoxicity. Inflammasomes are 
inducible high molecular weight protein complexes that are involved in 
many inflammatory pathological processes. Recently, Aβ was found to 
activate the NLRP3 inflammasome in microglial cells in vitro and in vivo 
thereby defining a novel pathway that could lead to progression of AD 
[101–103]. In this work, we review possible LPS and Aβ-induced 
inflammasome activation in the periphery and discuss how this could 
contribute to the pathogenesis of AD. Also we investigated about 
inflammasome role in primary microglia Aβ- uptake .  
 
The project is according to the following points: 
 Analyze expression profile of genes involved in the pathway of the 
inflammasome and NLRP3 protein expression on PBMCs of subjects 
with different diagnosis of AD and healthy subjects. 
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 Analyze the level of pro-inflammatory cytokines produced downstream 
of inflammasome activation pathway on patients’ PBMCs with 
Alzheimer's disease, mild cognitive impairment and healthy subjects.  
 Analyze microglia Aβ-clearance in response to the production of 
inflammatory cytokines in WT, APP or NLRP3 and ASC knockout mice. 
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2. MATERIALS AND METHODS 
2.1 PATIENTS AND CONTROLS 
One-hundred elderly Italian individuals were enrolled in the study: 20 
individuals with a diagnosis of mild cognitive impairment [MCI] [MMSE 
score>24], 21 patients with moderate Alzheimer’s disease [MMSE score 
19-23], 19 patients with severe Alzheimer’s disease [MMSE score<19] and 
40 age-and sex-matched healthy controls [HC] were enrolled in the study. 
The clinical diagnosis of Alzheimer’s disease was performed according to 
the NINCDS-ADRDA work group criteria [104] and the DMS IV-R 
[American Psychiatric Association,1994] [105]. All subjects underwent 
complete medical and neurological evaluation, as well as laboratory 
analysis, and CT scan or MRI. Additional investigations [e.g., EEG, SPECT 
scan, CSF examination, etc.] were performed in some cases to exclude 
reversible causes of dementia. Neuropsychological evaluation and 
psychometric assessment were performed with a neuropsychological 
battery that included the Mini- Mental State Examination [MMSE] [106]. 
Digit Span Forward and Backward, Logical Memory and Paired Associated 
Words Tests, Token Test, supra Span Corsi Block Tapping Test, Verbal 
Fluency Tasks, Raven Colored Matrices, the Rey Complex Figure, Clinical 
Dementia Rating Scale [CDR] [107], and the Hachinski Ischemic Scale. 
Individuals with a diagnosis of MCI were selected among subjects seen at 
our Memory Disorders Outpatients Service for the diagnostic evaluation of 
memory complaints without difficulties in daily activities. MCI diagnosis was 
based on Petersen’s criteria [108] as follows: 1] reported cognitive decline, 
2] impaired cognitive function, 3] essentially normal functional activities, 
and 4] exclusion of dementia. The healthy controls were selected according 
to the SENIEUR protocol for immuno-gerontological studies of European 
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Community’s Control Action Program on Aging [109,110] and were 
unrelated healthy spouses of Alzheimer’s disease and MCI patients. The 
cognitive status of HC was assessed by administration of MMSE [score for 
inclusion as normal control subjects > 28]. Written consent was obtained 
and ethical approval was granted by the Ethics Committee of the Don C 
Gnocchi Foundation in Milano, Italy. 
2.2 BLOOD SAMPLE COLLECTION AND CELL SEPARATION 
Whole blood was collected by venopuncture in Vacutainer tubes containing 
ethylenediaminetetraacetic acid [EDTA] [Becton Dickinson & Co., 
Rutherford, NJ, USA]. Peripheral blood mononuclear cells [PBMCs], 
consisting of T lymphocytes, B lymphocytes, monocytes and natural killer 
cells, were separated on lymphocyte separation medium [Fycoll-Hypaque, 
Organon Teknika Corp., Durham, NC, USA] and washed twice in PBS; 
viable leukocytes were determined by trypan blue exclusion. 
2.3 CELL LINE 
Microglia are key glial elements of the central nervous system [CNS] and 
considered the major immunocompetent cells in the brain. Microglia, along 
with neurons, have an important role in brains function and inflammatory 
neuropathology especially in all neurodegenerative disorders. They have 
been used in the different neurological disease models over the years. 
Microglial and neuronal primary cultures are being used widely to 
understand the diseases mechanisms in neurodegenerative research area. 
There are several microglia and neuronal like cell-lines are available to use 
as a preliminary source of information. These cell-lines have been shown 
high similarities in phenotype/morphology, cytokine profile and most 
importantly genomic resemblance.  
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2.4 ANIMAL 
Wild type mice [Jackson Lab] and NLRP3, ASC knockout animals [kind gift 
from AG Latz] were used in the current experiment. Animal care and 
handling was performed according to the declaration of Helsinki and 
approved by the local ethical committee. 
2.5 CELL CULTURES 
- PBMC [1x10
6
/ml] were cultured in RPMI 1640 supplemented with 10% 
human serum, 2 mM L- glutamine, and 1% penicillin [Invitrogen Ltd, 
Paisley, UK] alone or were primed with 2 μg/ml LPS for 2 hours [Sigma-
Aldrich] before stimulation with 10 μg/ml of 1-42 amyloid-beta peptide 
soluble oligomer [Aβ42] [Sigma-Aldrich, St. Luis, MO, USA] for either 4 
[PCR], or 24 hours [FACS, confocal microscopy and ELISA] at 37°C in a 
humidified 5% CO2 atmosphere.  
- Primary Microglial Cell Culture were prepared from postnatal day 1 mouse 
pups were stripped of meninges. Primary microglia was prepared from wild 
type, NLRP3 and ASC knockout. Whole brains were dissected in HANKs 
[Hank's Balanced Salt Solut ion ] salt solution [Biochrom, L2015], 
washed 3 times with HANK solution and trypsin was added and incubated 
at 37°C about 10 minutes. After mechanical disruption with a 10 mL 
sarstadt pipette the solution was centrifuged at 4°C at the speed of 1200 
rpm for 10 minutes. Remaining brain pellet was mixed in the microglia 
complete Medium: DMEM [Dulbecco's Modif ied Eagle Medium] plus 
10% FCS [Fetal Calf serum] and 5% Streptomycin/Penicillin. For each two 
brains one T/75 bottles was used and placed in unified medium containing 
33 
 
5% CO2 at 37°C and mixed cultures were grown for almost 12-14 days until 
harvested. By tapping the flasks and collecting the microglia-enriched 
containing medium. Microglia were pelleted by centrifugation [1000 rpm, 5 
min], resuspended in complete DMEM-medium and were plated 6-well 
plates at 1x106 cells/well for the experiments that follow; 
I experiment: cells were plated unstimulated  and stimulated with LPS [200 
ng/ml] for 2, 4, 6, 12 and 24 hours; cells were washed 2 times in PBS and 
supernatants were collected for ELISA analysis.  
II experiment: cells were un-treated and stimulated with LPS [200 ng/ml] for 
1 hour, washed 2 times in PBS and fresh medium was added; after 1, 5 
and 11 hours the supernatant were collected.  
III experiment: un-treatment condition and LPS [200 ng/ml] alone for 24 
hours or plus ATP [1 uM] for 30 minutes or Nigericin [1.34 uM] for 2 hours 
treatment. Supernatants and cells were collected for ELISA and Western 
Blot analysis. 
For Aβ- phagocytosis flow cytometry analysis cells were primed in the 
same condition with LPS, ATP and Nigericin; then the cells were washed 
two times in PBS and was added fresh conditioned medium with Beta-
Amyloid [1-42] -Lys [Biotin], green fluorescent probe [FAM]-labeled [500 
nM] for 4 hours.  
Plated cells were grown in supplemented media 24 hours and then the 
medium was replaced with serum-free DMEM overnight.  
2.6 RNA EXTRACTION AND REVERSE TRANSCRIPTION  
RNA was extracted from un-stimulated, LPS-stimulated  and LPS-primed 
and Aβ1-42-stimulated-PBMC. RNA was extracted from cultured PBMCs by 
using the acid guanidium thiocyanate–phenol–chloroform method. The 
RNA was dissolved in RNase-free water and purified from genomic DNA 
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with RNase-free DNase [RQ1 DNase; Promega, Madison, WI]. One 
microgram of RNA was reverse transcribed into first-strand cDNA in a 20 μl 
final volume containing 1 μM random hexanucleotide primers, 1 μM oligo 
dT and 200 U Moloney murine leukemia virus reverse transcriptase 
[Clontech, Palo Alto, CA]. cDNA were evaluated for GAPDH expression by 
Real Time PCR to test the quality of RNA.  
2.7 INFLAMMASOME SIGNALING PATHWAY 
For Gene expression of inflammasome components and signaling 
pathways has been used the human Inflammasomes RT2 Profiler PCR 
Array [Qiagen PAHS-097Z], which includes  a set of optimized primer 
assays allowing the detection of mRNA transcripts of 84 genes related to 
the inflammasomes and their functions [Tab4], as well as five 
housekeeping genes, in a 96-well plate by real-time PCR. Individual 
specimens were pooled according to MMSE scores to create four groups of 
different disease states. Eight pooled samples, corresponding to treated 
and untreated cells from severe AD, moderate AD [MILD], MCI and HC, 
were subjected to the PCR arrays. Data was analyzed by the comparative 
Ct method using GAPDH as the reference gene. Results are expressed as 
the fold changes between each AD/MCI/MILD pool and HC treated and 
untreated cells from each disease state. Heat maps were generated and 
genes hierarchically clustered by Euclidean distance and single linkage 
using TIGR MultiExperiment Viewer [MeV] v4.9 [109]. 
2.8 REAL TIME QUANTITATIVE REVERSE TRANSCRIPTION  
 Real Time quantitative Reverse Transcription PCR [RQPCR] was 
performed on a ABI Prism 7000 instrument [PE Applied Biosystems, Foster 
City, CA, USA] with gene specific primers and the SybrGreen chemistry to 
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confirm the gene expression changes observed by arrays. All primers, 
casp1-5-8, IL1β, IL18, IL33, IL37, NLRP1 and NLRP3 used were cDNA 
specific and were purchased from Qiagen [Venlo, PB]. Amplification of 
specific PCR products was detected using the RT2 SYBR Green Fluor with 
a 25 μl final volume of 12.5 μl RT2 qPCR Mastermix [Qiagen] 10.5 μl H2O, 
1.0 μl of either diluted template and 1.0 μl RT2 qPCR Primer Assay. 
Results were expressed as ∆∆Ct and presented as ratios between the 
target gene and the GAPDH housekeeping mRNA.  
2.9 FLOW CYTOMETRY IMMUNOFLUORESCENT STAINING 
Unstimulated and LPS-primed and Aβ1-42-stimulated-PBMC were stained 
with anti-CD14-PC7 [clone RMO52, isotype mouse IgG
2a
, Beckman 
Coulter] mAb for 30 minutes at 4°. Cells were then washed, treated with 
FIX and PERM Cell kit [eBioscience, San Diego, CA, USA], and stained 
with anti- NLRP3-PE [clone 768319; isotype rat IgG2a R&D], -NLRP1-APC 
[isotype rabbit polyclonal IgG Proteintech, Chicago, IL, USA], Caspase 5-
FITC [isotype rabbit polyclonal; LSBioSciences,Inc, Seattle, WA USA], -
ASC-FITC [clone HASC-71; isotype mouseIgG1k, eBioLegend], IL-1β 
 [clone 8516; isotype mouse IgG1; R&D] -IL33-APC [clone 39412 
isotype rat IgG2B R&D], or IL37-PE [clone 6A6, isotype mouse IgG1k 
LSBioSciences, Inc] mAb for 30 minutes at 4°. FLICA staining of active 
caspase 1 and caspase 8 was performed using the green fluorescent probe 
FAM-YVAD-FMK caspase 1 and FAM-LETD-FMK caspase 8 [AM-FLICA, 
Immunochemistry, Bloomington, IN, USA]. NLRP1, Caspase5 and ASC 
were conjugated using the Lightning-Link APC or FITC conjugation kit 
[Innova Biosciences, Cambridge, UK].  
For phagocytosis assay, stimulated and control mouse primary microglia 
WT, NLRP3−/− and ASC−/− cells were stained with 7-ADD mAB for 
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vitability. Cells were finally analyzed using a Beckman-Coulter GALLIOS 
flow cytometer equipped with a single 15 mW argon ion laser operating at 
488 nm and interfaced with CXP Software 2.1. Two-hundred- thousand 
cells were acquired and gated on CD14 expression and side scatter 
properties. Isotype control or single fluorochrome-stained preparations 
were used for color compensation. 
2.10 ELISA IMMUNOASSAYS  
Human IL1β, IL18 and IL33 concentration was determined in unstimulated 
and in LPS-primed and Aβ1-42-stimulated-PBMC supernatants. Levels of 
murine TNFα and IL-1β were determined in supernatant of LPS stimulated 
Primary Microglia cells and control. 96-well plates were coated overnight 
with monoclonal anti-human IL1β, IL18 or IL33 and anti-mouse TNFα or 
IL1β capture antibody [R&D Systems], washed with phosphate-buffered 
saline [PBS] containing 0.05% Tween-20 and blocked with PBS containing 
1% bovine serum albumin [BSA], 5% sucrose and 0.05% NaN3 following 
by a wash step. Successive treatments with washing in between were done 
with samples or standards, biotinylated polyclonal anti-human IL1β, IL18 or 
IL33 and anti-mouse TNFα or IL1β detection anti- body [R&D Systems] in 
20 mM Tris with 150 mM NaCl and 0.1% BSA, streptavidin–horseradish 
peroxidase [HRP] conjugate, and equal volumes of HRP substrates 
3,3',5,5'-tetramethylbenzidine and hydrogen peroxide. The reaction was 
stopped by the addition of 1% H2SO4 solution. The optical density of each 
sample was analyzed at 450 nm with a reference reading at 630 nm using 
a SpectraMax 340 absorbance plate reader [Molecular Devices, Union City, 
CA]. The cytokines concentration in the experimental samples was 
calculated from a mouse TNFα or IL1β and human IL1β standard curve of 
15–2000 pg/ml; from human IL18 and IL33 standard curve of 15-1000 
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pg/ml. When necessary, samples were diluted to fall within the standard 
curve. All cytokine levels are reported as pg/mL and are based on the 
output from 106 cells in each well. 
2.11 CONFOCAL MICROSCOPY ANALYSIS 
Un-stimulated or LPS-primed or Aβ1-42- or LPS-primed an Aβ1-42 stimulated-
PBMC were cultured on chamber slide [Lab Tek Nalge Nunc Intern. 
Naperville IL USA] for 24 h at 37°C. After washing off non adhering PBMC, 
monocytes grown on chamber slide were fixed in 4% paraformaldehyde in 
PBS for 15 min and treated for 1 hour at room temperature with FLICA 
staining of active caspase 1 or caspase 8 using green fluorescent FAM-
YVAD-FMK probes, following the procedures suggested by the 
manufacturer [AM-FLICA]. Cells were then treated with FIX and PERM Cell 
kit [eBioscience], and stained with PE or APC or FITC conjugated -mAbs 
specific for NLRP3 or NLRP1 and ASC or caspase 5 for 24 hours at 4°C. 
Finally cells were fixed with paraformaldehyde 1% for 15 minutes, washed 
and mounted on slides using the Vectashield Mounting Medium [Vector 
Laboratories, Inc, Burlingame, CA, USA]. Fluorescent images were 
acquired on a Leica TCS DMRE spectral laser-scanning confocal 
microscope [Leica Microsystems, Wetzlar, Germany] with the appropriate 
filters and laser [488, 633] and a 63X objective lens. Image analysis was 
performed using the Leica Confocal Software and co-localization index with 
ImageJ Software. Co-localization indexes were calculated using the plug in 
JACoP [Justo Another Co-localization Plugin] [110]. The summarized 
colocalization efficiency data was expressed as Pearson correlation 
coefficient [PCC] as previously described [111,112,113]. Briefly this 
coefficient measure the significance of true colocalization. The significance 
test is derived to evaluate the probability that the measured value of r from 
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the two colors is significantly greater than values of r that would be 
calculated if there was only random overlap. This test is performed by 
randomly scrambling the blocks of pixels [instead of individual pixels, 
because each pixel's intensity is correlated with its neighboring pixels] in 
one image, and then measuring the correlation of this image with the other 
[unscrambled] image. The test produce values in the range −1 + 1, 0 
indicating that there is no discernable correlation and −1 and +1 meaning 
strong negative and positive correlations, respectively. 
2.12 WESTERN BLOTTING 
Unstimulated and LPS-primed and Aβ1-42 stimulated-PBMC were washed 
and lysed with M-PER Mammalian Protein Extraction Reagent with 
phosphatase and protease inhibitors  [10 µl/ml, HaltTM Protease and 
Phosphatase Inhibitor Cocktail, [Thermo Scientific Inc], Rockford, IL, USA]. 
After protein estimation using the Bradford Assay reagent [Bio-Rad] 20 ųg 
of cell lysate was resolved by electrophoresis on a 10% SDS-
polyacrylamide gel under reducing conditions. Proteins were then 
transferred to PVDF membrane by electrophoretic blotting and blocked for 
1 hour in blocking buffer [Blocker BLOTTO Blocking Buffer, Thermo 
Scientific]. Membranes were then incubated overnight with sheep anti-
recombinant NALP3 [AF6789, R&D Systems] or for 1 hour with sheep anti 
beta-actin antibody [AF4000, R&D Systems], then diluted 1:1000 in 
blocking buffer followed by HRP-conjugated anti-sheep IgG [HAF016, R&D 
Systems]. Bound antibodies were visualized with a chemiluminescence 
development reagent [LiteAblot TURBO, Euroclone, Italy] according to the 
manufacturer’s instructions. Bands were imaged in a Gel-Doc Cabinet and 
the density of the image was measured and normalized with beta-actin. 
Mouse Primary Microglia: supernatants and extracts of control and treated 
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primary microglia cells were used. Cells were lysed with RIPA buffer [20 
mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% 
deoxycholic acid, and 0.1% SDS] supplemented with protease inhibitor 
cocktail [Sigma]. Collected lysates were centrifuged at 9000 ×g to remove 
cell debris and the supernatants were mixed 1:1 with Laemmli SDS sample 
buffer [Bio-Rad] containing 5% β-mercaptoethanol. Samples were 
denatured [95°C, 5 minutes] and separated on 15% Tris-HCl gels [Ready 
Gel, Bio-Rad] under denaturing conditions [25 mM Tris, 192 mM glycine, 
0.1% SDS at pH 7.8] using a Mini Protean 3 Cell [Bio-Rad]. Gels were 
transferred to PVDF membrane [Milipore] in transfer buffer containing 25 
mM Tris base, 192 mM glycine, and 10% methanol at pH 8.3 using a Tank 
VEP-2 electroblotting system [Owl Separation Systems]. Following protein 
transfer, the membrane was blocked for 1 hour at room temperature with 
TBST containing 5% BSA. Cell extracts supernatants were analyzed by 
immunoblot using goat anti-IL1β [R&D], mouse anti-NLRP3 [Cryo-2], rabbit 
anti-ASC [AL177], mouse anti-Caspase-1 [Casper-1] [all three from 
Adipogen], and mouse anti-alpha-tubulin [Abcam]. All first antibody were 
diluted into 1:1000 final concentration of TBST and 3% BSA and incubated 
over-night at 4°C; Secondary antibodies were used at 1:20000 as final 
concentration, incubated for 1 hour at room temperature. The membrane 
was washed 3 times 1X TBST for 5-10 minutes and developed with 
chemiluminescence agent ImmobilionTM [Milipore]. The protein bands 
were analyzed using analysis tools provided by Quantity One software. The 
optical intensity of the desired sized band was normalized with α- tubulin or 
β -actina from the respective well. 
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2.13 IMMUNOCYTOCHEMISTRY 
The immunostaining experiment was performed in 24 well plates. 450.000 
microglial cells/condition were cultured on poly-L-lysine coated coverslips 
and fixed with paraformaldehyde [4% in PBS] after LPS alone, LPS primed 
and AβFAM-labeling stimulation and unstimulated condition. Cells were 
incubated overnight at 4°C with rabbit anti-Iba1 [1:100, Biocare Medical]. 
After washing with PBS, cells were incubated with anti-rabbit Alexa Fluor 
594 secondary antibodies for 1-2 hours. Cells were then washed with PBS 
and mounted with DAPI-Fluoromount G [SouthernBiotech, USA].The 
imaging was performed with the help of fluorescence microscope from 
Olympus BX-61. For enhanced and congruous focusing, z-stack correction 
was employed. During every procedure, six images along z-axis spaced at 
distance of 1.6 μm were captured and then best suited image of the various 
channels were merged. Cell P Olympus software was utilized for imaging 
purpose. 
2.14 STATISTICAL ANALYSES 
Quantitative data were not normally distributed [Shapiro–Wilk test] and are 
thus summarized as median and Interquartile Range [IQR] [25° and 75° 
percentile]. Comparisons between groups were analyzed used a Kruskal-
Wallis ANOVA for each variable. Comparisons among the different groups 
were made using a 2-tailed Mann-Whitney U test performed for 
independent samples. Data analysis was performed using the MedCalc 
statistical package [MedCalc Software bvba, Mariakerke, Belgium].  
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3. RESULTS 
3.1 INFLAMMASOME PROTEINS ARE UP REGULATED IN LPS-
PRIMED AND A1-42-STIMULATED-MONOCYTES OF AD 
PATIENTS 
 
mRNA expression of 84 genes involved in the assembly of the 
inflammosome, its activation, and its down-stream signalling was quantified 
by qPCR in all patients and controls. Data obtained in LPS-primed and Aβ1-
42-stimulated-monocytes showed the presence in MILD and severe AD, as 
well as in MCI, of a significant up-regulation involving genes that codify for 
the proteins that form the inflammasome. Notably, though, whereas all the 
proteins necessary for the assembly of a functional inflammasome were up 
regulated in AD, NLRP 1 and 3 and caspase 8 alone were increased in 
MCI. To summarize: 1] the expression of NLRP1, NLRP3 and caspase 8 
was greatly increased [nFold>10] in all groups of patients compared to HC, 
with no detectable differences being observed between individuals with a 
diagnosis of AD or MCI; 2] ASC [PYCARD], caspase 1 and caspase 5 
expression was increased [nFold ≥10] in AD but not in MCI patients. 
Finally, minor differences were seen between patients and controls in the 
level of expression of these genes in monocytes-stimulated with either LPS 
or Aβ1-42 alone, both stimuli, neverthertheless induced IL1β and IL6 up-
regulation [nFold>10] in HC alone [Figure 12]. 
RT-PCR performed on each individual specimen was used to verify the 
expression of NLRP1, NLRP3, caspase 1, caspase 5 and caspase 8 in LPS 
and Aβ1-42 –stimulated monocytes of patients and HC. Results of mRNA 
expression confirmed that: 1] NLRP1, NLRP3 and caspase 8 are 
significantly increased in AD and MCI individuals compared to HC [p<0.05], 
with the highest values observed in severe AD, and 2] caspase 1 and 
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caspase 5 are significantly increased in AD compared to MCI and HC 
[Figure 13A]. 
 
3.2 UP-REGULATION OF INFLAMMASOME-RELATED 
CYTOKINES IN LPS-PRIMED AND A1-42- STIMULATED-
MONOCYTES OF AD PATIENTS 
Stimulation of monocytes with either LPS or Aβ1-42-alone resulted in the 
moderate increase of IL1β and IL6 expression; notably this was not 
sufficient to trigger inflammasome assembly as no differences were detect 
in these conditions either in NLRP3 or IL18 mRNA [Figure 1]. Once cells 
were activated with LPS and Aβ1-42, nevertheless, both IL1β [nFold>10] and 
IL18 [nFold ≥10] mRNA were significantly increased in severe and MILD 
AD compared to MCI and HC. Results obtained by single-PCR confirmed 
that in these experimental conditions IL1β and IL18 mRNA [p<0.05 vs. all 
other groups] is significantly increased in severe and MILD AD with the 
highest values in severe AD [Figure 13B]. 
IL33 and IL37, two relatively novel cytokines that are members of the IL-1 
family, were analyzed as well in the study. We found that IL33 gene 
expression was greatly increased in MCI [nFold>10] compared to AD and 
HC; no significant differences, on the other hand, were observed in IL37 
gene expression in any of the groups analyzed [Figure 1]. Single RT-PCR 
confirmed these results [Figure 13C].  
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3.3 NLRP3 PROTEIN IS SIGNIFICANTLY AUGMENTED IN LPS-
PRIMED AND A1-42 STIMULATED- MONOCYTES OF AD AND MCI 
PATIENTS 
The expression of NLRP3, the best-characterized protein within the 
inflammasome complex was investigated next by Western Blot analyses in 
LPS-primed and Aβ1-42-stimulated-PBMC of all patients and controls. 
Different NALP3 isoforms are known: the long form [118 KDa] is prevalent 
in cell lines [THP1 or Jurkat] while the short one [NLRP3s 75 KDa] is seen 
in primary immune cells [114]. Results of analyses performed on whole-cell 
lysates confirmed that NLRP3 expression is significantly increased in AD 
and MCI individuals with the highest amounts of protein being detected in 
patients with a diagnosis of severe AD [Figure 14].  
3.4 LPS-PRIMED AND A1-42 STIMULATED MONOCYTES THAT 
EXPRESS INFLAMMASOME PROTEINS ARE SIGNIFICANTLY 
AUGMENTED IN AD 
Peripheral CD14+ monocytes that express NLRP3 or co-express NLRP3 
and ASC, NLRP3 and caspase 1, or NLRP3 and caspase 8 were 
augmented in LPS-primed and Aβ1-42-stimulated-cells of both groups of AD 
patients compared to MCI individuals and HC. The Fluorochrome Inhibitor 
of Caspases [FLICA] kit was used to analyze the presence in cells of active 
caspases; in this method, once inside the cell, the FLICA inhibitor probe 
binds covalently to active caspases [p20] alone. Staining of active caspase 
1 and caspase 8 inhibitors was performed using the green fluorescent 
probe FAM-YVAD-FMK and FAM-LETD-FMK respectively. Results showed 
that 1] CD14+/NLRP3+, CD14+/NLRP3+/caspase1+, and 
CD14+/NLRP3+/Caspase8+ immune cells were significantly increased in 
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severe AD patients alone compared to MCI and HC [p<0.05] and 2] 
CD14+/NLRP3+/ASC+, cells were augmented both in severe and MILD AD 
compared to MCI and HC [MCI and HC vs. moderate AD p<0.05; vs. 
severe AD p<0.01] [Figure 15A]. 
Finally, LPS-primed and Aβ1-42 stimulated NLRP1-expressing CD14 cells 
were significantly increased as well in both groups of AD patients compared 
to MCI and HC [p<0.05] [Figure 15B]. These results confirm those obtained 
in PCR analyses and indicate that, even if some inflammasome 
components are up regulated in MCI, fully functional inflammasomes are 
not assembled in this situation.  
3.5 CO-LOCALIZATION OF INFLAMMASOME PROTEINS IN LPS-
PRIMED AND A1-42 STIMULATED MONOCYTES BY CONFOCAL 
MICROSCOPY ANALYSES 
Aggregation and activation of inflammasome complexes was further 
analyzed by evaluating the co-localization of NLRP3 and NLRP1 with ASC, 
caspase 1 or caspase 8 by confocal microscopy. Co-localization efficiency 
was calculated using the Pearson co-localization coefficient [PCC]. Results 
showed a clear co-localization of NLRP3 with ASC, caspase 1 and caspase 
8 in Aβ1-4242-stimulated and LPS-primed- monocytes of AD patients alone; 
no co-localization could be detected in untreated cells [data not shown]. In 
particular: 1] NLRP3/ASC NLRP1/ASC and NLRP3/caspase1 co-
localization was increased in both groups of AD patients compared to HC 
and MCI; 2], NLRP3/caspase8 and NLRP1/caspase5 co-localization was 
increased in severe AD alone; and 3] NLRP1/caspase1 co-localization was 
seen only in cells of MILD AD patients. In all cases, with the exception of 
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the NLRP1-caspase 1 complex, the highest PCC values were detected in 
cells of patients with severe AD disease [Figure 16 and Table I]. 
3.6 INFLAMMASOME-RELATED CYTOKINES PRODUCTION IN 
LPS-PRIMED AND A1-42 STIMULATED - MONOCYTES OF AD 
PATIENTS  
Aggregation of the inflammasome results in the down-stream production of 
pro-inflammatory cytokines. Because FACS and confocal microscopy data 
indicated that the different subunits that compose the inflammasome do 
aggregate in LPS-primed and Aβ1-42--stimulated- monocytes of AD patients, 
and PCR analyses showed that mRNA for these cytokines is increased in 
monocytes of AD patients, IL1β IL-18, IL33 and IL37 were measured next. 
Results showed that the concentration of IL1β IL-18 in supernatants was 
significantly increased in both groups of AD patients compared to MCI and 
HC [IL1β p<0.05; IL18p<0.01] [Figures 17A and 17B]. Whereas lack of 
proper reagents prevented IL18-expressing cells to be analyzed by FACS, 
the percentage of CD14+/IL1β+ cells was significantly increased as well in 
MILD and severe AD compared to MCI and HC [p<0.05] [Figure 17A]. The 
fact that these cytokines were not increased in MCI is not surprising 
considering that in this condition NLRPs but not ASC expression was 
augmented, thus preventing the assembly of a functional inflammasome; 
these data confirm the findings obtained with FACS and confocal analyses. 
IL33 could not be quantified in supernatants [data not shown], probably 
because the inflammatory mature form of this cytokines is not cleaved and 
secreted. Results obtained by flow-cytometry, nevertheless showed that 
CD14+/IL33+ cells were increased in MCI and in MILD AD, with the lowest 
percentages of these cells seen in severe AD [p<0.01] [Figure 17C]. 
Notably this cytokine was shown to have a multifaceted protective role 
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against Alzheimer’s disease and to negatively modulate NF-kB activity, 
dampening inflammation. Finally, CD14+/IL37+ cells were marginally 
increased in AD compared to MCI and HC [Figure 17D]. 
 
3.7 NLRP3 AND ASC REGULATE CYTOKINES PRODUCTION BY 
MICROGLIA UPON LPS EXPOSURE 
Lipopolysaccharide [LPS] can trigger series of inflammatory reactions in 
phagocytes such as macrophages. LPS is a glycolipid derived from the 
membrane surface of gram negative bacteria [endotoxin]. In in vitro 
experiments using cultured microglia, LPS has generally been used for cell 
activation. Although the time course of LPS-induced activation of microglia 
is of interest, data reported in literature are contrasting. Thus in the first 
experiment we quantified cytokines production in LPS-stimulate cells for 
different times. As expected, first TNFα was release after 2h, second IL1β 
within 12 h increasing both over 24 h [Figure 18A]. Noteworthy: NLRP3 and 
ASC KO microglia displayed significantly attenuated levels of IL1β release 
in response to LPS; surprisingly TNFα level was less pronounced in NLRP3 
KO compare to WT and ASC KO cells [2000pg/ml NLRP3vs 40000pg/ml 
for WT and ASC] [Figure 18A]. The same results were also obtained with 
indirect stimulation [Figure 18B]. In contrast IL18 level was not detectable in 
any condition. Collectively, these results demonstrate that as provided in 
WT microglia stimulated with TLR4 agonist, as LPS, is evident IL1β 
production for the alternative inflammasome pathway activation; also in 
NLRP3 and ASC KO microglia was not assessed any production IL1β 
confirming  inflammasome function in the production of inflammatory 
cytokines.  
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3.8 THE NLRP3/ASC/CASPASE1 AXIS REGULATES IL1 
PROCESSING IN MOUSE PRIMARY MICROGLIA 
In order to better investigate IL1β production in inflammasome-manner 
activation, we stimulated LPS-primed murine microglia NLRP3 and ASC 
KO with ATP or Nigericin; as a result of the inflammasome activation IL1β, 
quantified on ELISA test, was very high in WT cells after Nigericin 
stimulation[Figure19]. The fact was confirmed by WB; Pro-IL1β was 
produced in the same way both in WT and KO conditions; in ATP 
treatment, pro-IL1β and pro-Casp1 increase compare to control, but only 
after inflammasome activation, cleaved IL1β and Caspase 1 [p20] were 
release-out of the cells [Figure 20]. Indeed in KO condition, microglia 
treated with ATP or Nigericin increase the production of inflammatory 
cytokines but cells can not release them. ASC protein was also evaluated; 
ASC, expressed constitutively in the cells, was greater produced in NLRP3 
KO cells [Figure 20].  
3.9 A-PHAGOCYTOSIS AND NEUROINFLAMMATION IN 
MICROGLIA 
Primary murine microglia were evaluated to determine whether 
proinflammatory environments could also regulate their capacity to 
stimulate phagocytosis. Microglia were treated with LPS for 24h to induce a 
pro-inflammatory environment as was demonstrated previously; by flow-
cytometry analysis was not detected difference between LPS-primed and 
FAM-Aβ1–42 stimulated cells compare to the control condition [FAM-Aβ1–42 
alone]. The same results was observed with indirect-LPS stimulated WT 
and KO cells [Figure 21]. 
LPS and inflammasome activators, such as ATP or Nigericin, treated- WT 
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cells were also evaluated in flow cytometry in order to asses if 
inflammasome activation can modify Aβ -uptake. Although inflammatory 
cytokines production has been well established, we didn’t found significant 
statistical difference in Aβ1–42-phagocytosis [Figure 22].The idea is that the 
FAM-Aβ can bind cells non-specifically; ICC experiment [Figure 23] on 
microglia confirmed that in all of the conditions Aβ1–42 is in the proximity of 
the cells, as shown by the green background.  
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4. DISCUSSION 
It is now widely recognized that the "inflammation” of nervous structures, or 
“neuroinflammation”, is a common feature of all neurological disorders. For 
example, in multiple sclerosis the CNS appears infiltrated by various 
leukocyte subpopulations [115]. Moreover, even when an inflammatory 
infiltration is not obvious, as in Parkinson's disease or in Alzheimer's, there 
is still an intense microglial activation with a consequent increase in CNS of 
many inflammation mediators [116]. In other tissues, the inflammatory 
reaction is a natural healing process with respect to a damaging insult and 
therefore, if a direct and developed properly, a response advantageous for 
the organism. Not surprisingly, in neuroinflammation it is found beneficial 
effects, such as neuroprotection, the mobilization of neural precursor cells 
for repair of the damage, remyelination and axonal regeneration [115,116]. 
But in the other hand, a vast literature reports that neuroinflammation 
produces adverse and harmful consequences [117] and shows a close 
correlation between neuroinflammation and neurodegenerative disease, 
although it appears unclear whether the onset of inflammatory processes 
causing, or is the result of neurodegeneration [117]. 
As the idea of a possible association between Alzheimer's disease and 
inflammatory process it was initially strongly rejected by the scientific 
community, there is now a broad convergence in a state that the 
neuroinflammatory components play a crucial role in Alzheimer's disease 
[118,119,120]. Several scientific evidence reveal up-regulation of 
proinflammatory molecules such as cytokines or chemokines and 
complement factors in brains of AD individuals  [121,122] and that activated 
microglia cells release ROS [123]. Furthermore, the presence of activated  
microglia, localized near the sites of deposit of amyloid peptide, has been 
demonstrated in murine models that over-express APP, either on tissue 
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from patients with AD [124]. It is widely accepted that the presence of 
damaged neurons, neurofibrillary tangles and deposits of amyloid peptide 
in the brain of AD are due to establishment of localized and chronic 
inflammatory processes. 
However, these morphological characteristics [plaques, tangles and 
neuronal injury], the pathognomonic disease, are also found in patients in 
pre-clinical stages of the disease and yet it is not known when the 
inflammatory process develops and whether it is a primary or secondary 
event in the evolution towards the disease and its progression.  
To better investigate this inflammatory process characteristic of AD 
subjects and to improve knowledge which will enable a greater 
understanding of the mechanisms underlying the disease, in the currently 
study we demonstrate the possible role of the inflammasomes in the 
neuroinflammation that accompanies Alzheimer’s disease analyzing 
peripheral immune cells of patients with Alzheimer’s disease and mouse 
primary microglia. 
Inflammasomes are intracellular complexes formed by the assembly of 
multiple subunits that regulate the maturation and the secretion of pro-
inflammatory cytokines [1]. At least four different inflammasomes are 
described; the NLRP3, in particular, is suspected to play a role in the 
pathogenesis of Alzheimer’s disease. Thus, in animal models, NLRP3 
upregulation was shown to induce the production of IFN1β by microglia 
[102]; and, on the other hand, its deficiency results in a decreased 
deposition of amyloid-β in the APP/PSI animal model of Alzheimer’s 
disease [102,125,126]. Inflammasome complex activation requires the 
assembly of NLRP3 with ASC to produce active form of caspase1, 
IL1βand IL18. In our laboratory we have previously shown that peripheral 
monocytes in Alzheimer’s disease are characterized by an inflammatory 
profile and are involved in the induction of both innate immune responses 
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via TLR stimulation and of acquired immunity, possibly secondarily to the 
presentation of Aβ -peptides in an MHC-restricted fashion [127,128]. So, 
these encouraging results obtained on PBMCs have provided the basis for 
the development of my research project aimed to extend the knowledge of 
the inflammatory component in the various stages of the development of 
AD pathology and population control with cognitive abilities in the normal 
range. The purpose is to identify the presence of indicator signals, changes 
of particular inflammatory molecules expression, which might be 
considered indicators of a possible pathological condition still 
symptomatologically silent or otherwise of a possible evolution in time to 
pathology. 
In the first part of my research project, all experiments were performed on 
PBMC of AD, MILD, MCI patients and HC; instead in the second part of the 
project, developed at the research laboratories of the University of Bonn, 
the experiments were performed on mouse primary microglia cells.  
I'll comment briefly achievements. 
The NLRP3 is the best known inflammasome complex; its canonical-
activation requires the assembly of NLRP3 with ASC to produce active form 
of caspase1, IL1β and IL18. We observed that the mRNA expression of 
these proteins was significantly increased in severe and moderate 
Alzheimer’s disease patients. Inflammasome assembly leads to the 
production of proinflammatory cytokines; IL-1β and IL18 mRNA and 
secretion were indeed significantly increased in AD. Interestingly, 
stimulation of cells with Aβ142 alone was sufficient to induce IL1β mRNA 
expression, but LPS priming resulted in a significantly increased production 
of IL1β and in the generation of IL18 in AD alone, indicating that these 
experimental conditions result in the assembly of fully functional 
inflammasomes in cells of AD patients alone. Notably, transfection of 
human PBMC with siRNA specific for NLRP3 and ASC greatly reduced 
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IL1β production, confirming that the production of this cytokine is 
dependent on inflammasome assembly [129]. That IL1β plays a role in the 
pathogenesis of AD has been repeatedly shown. Thus, this cytokine 
induces a loss of phagocytic activity by the microglia [129], stimulates the 
hyperphosphorylation of tau protein [130], affects synaptic plasticity, inhibits 
long-term potentiation [LTP] and, as a consequence, impairs learning and 
memory processes [131][132]. IL18 has been involved in AD as well, even 
if fewer data are available on this cytokine. Thus, increased amounts of 
IL18 were detected in the brain [133], plasma [134] , and peripheral blood 
lymphocytes of AD [135], and the expression of the IL-18R complex is 
greatly augmented in peripheral blood cells of MCI and AD individuals. 
[136]. Finally, recent data indicate that IL18 directly stimulates Aβ 
production by human neuron-like cells, suggesting a key role for this 
cytokine in the pathogenesis of AD [137].  
  
NLRP1 and caspase8 mRNA were up-regulated in cells of severe 
Alzheimer’s disease patients; CD14+/ NLRP3+/caspase8+ cells were also 
increased in these individuals in whom the colocalization of caspase8 with 
NLRP3 was also detected. Recent data showed that caspase8 is not only 
an inducer of cell apoptosis, but, together with the Fas-Associated protein 
with death domain [FADD], interacts with NLRP3 and is required for 
caspase1 activation, as well as for IL1β and IL18 secretion [138]. Confocal 
analyses confirmed that caspase8 is present in the NLRP3 inflammasome 
complex, where it is involved in the cleavage of pro-caspase1 and IL1β, 
suggesting a direct role for caspase8 in caspase1 processing [139]. Our 
data support these findings as well as recent results indicating that 
caspase8 contributes to both NF-kB–dependent priming and post-
translational activation of the NLRP3 inflammasome [140]. Increased 
NLRP1 and caspase5 mRNA levels were detected as well in cells of 
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individuals with a diagnosis of severe Alzheimer’s disease; these proteins 
colocalized in CD14 cells, and higher percentages of 
CD14+/NLRP1+/caspase 5+ immune cells were seen in these patients. 
These data indicate that the NLRP1 inflammasome complex is activated as 
well in severe Alzheimer’s disease; notably, recent results indicate that 
SNPs in the NLRP1 gene are associated with Alzheimer’s disease [141]. 
Two other novel cytokines, IL33 and IL37 were analyzed as well in this 
study; these cytokines are members of the IL1β family and are produced 
upon activation of the inflammasome. Whereas no significant differences 
were seen in IL37, mRNA levels of IL33 were increased both in MILD 
Alzheimer’s disease and in MCI compared to the values observed in severe 
Alzheimer’s disease. Notably, percentages of circulating CD14+/IL33+ cells 
confirmed this observation, as these cells were increased both in MCI and 
moderate Alzheimer’s disease compared to severe Alzheimer’s disease 
and HC. IL33 and IL37 are dual function proteins with both intra and extra- 
cellular mechanisms of action as, besides being able to bind to their 
cognate receptors on target cells, they can act intracellular as nuclear 
factor. IL33 was shown to be reduced in AD brains [142]. This cytokine is 
believed to have a neuroprotective role secondary to its ability to reduce Aβ 
peptides secretion [143] and to activate the phagocytosis of Aβ-amyloid 
peptide by the microglia [144]. Even more recently [145], IL33 was shown 
to interact intracellularly with the NF-kB p65 subunit. The resulting IL33/NF-
kB p65 complex interferes with NF-kB–dependent transcription by impeding 
p65-mediated transactivation, thus playing a role as a negative modulator 
of NF-kB activity, with a dampening effect on inflammation. The observation 
that IL33 is increased in MCI and in MILD Alzheimer’s disease can thus be 
seen as an attempt of the immune response to reduce neuroinflammation. 
 
With regard to microglia, first we examined the cytokine production 
54 
 
implicated in mediating inflammasome activation in response to the largest 
array of PAMPs including LPS. Interestingly microglia from NLRP3 KO 
mice produced significantly less IL1β compared to WT cells, implicating a 
role for this cytoplasmatic receptor in this cytokine processing. We further 
studied the release of TNFα from microglia, as this is an another LPS-
induced mediator of neurotoxicity and inflammation [146, 147]. Similarly, 
LPS-induced release of TNFα was attenuated in NLRP3 KO cells 
suggesting that NLPP3 inflammasome, through activation of caspase1 and 
subsequent IL1 signaling, contribute to the proinflammatory production 
mediated by microglia. As support of this result, TNFα quantification in 
caspase1 and IL1R- deficient microglia was much lower compare to the 
WT, indicating that TNFα depends on autocrine and paracrine effects of 
IL1β after caspase1 activation [101]. 
Next we analyzed the downstream inflammasome adaptor ASC. 
Specifically, ASC contains a C-terminal pyrin domain, which serves to 
bridge NLRP3 and other NLRs that lack a caspase-recruiting domain 
[CARD] to caspase1 [147]. Therefore, the absence of ASC would impact 
additional cytoplasmic NLR sensors besides NLRP3 and potentially identify 
alternative routes for IL1β activation [148], but in our results IL1β release 
was very less in ASC KO compared to WT microglia in response to LPS. 
This finding indicates that both NLRP3 and ASC, that bridge caspase1, are 
operative in microglia. To determine whether microglial cytokine production 
was dependent on NLRP3 inflammasome activity, Primary microglia 
isolated from WT, NLRP3 or ASC KO mice were primed with LPS and 
stimulated with classical inflammasome activators, such as ATP and 
Nigericin. Results showed the release of IL1β and caspase1 only after ATP 
or Nigericin stimulation. In addition we also tested both NLRP3 and ASC 
knockout microglia cells; the incapacity of these cells to release IL1β 
confirmed our results. Surprisingly in all cases, these potent microglial 
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inflammasome activators did not results in detectable IL18 production; in 
according with Prinz’s work [149] IL18 is difficult to detect by western blot, 
specially in the supernatants.  
The role of microglia in the uptake and phagocytosis of amyloid in the brain 
was first noted in the early 90’s by Wisniewski and Frackowiak who utilized 
electron microscopy to visualize amyloid internalization [150-151]. They 
postulated that resident microglial cells associated with plaques in the AD 
brain played a role in the formation of the amyloid fibrils in the brain, but not 
its phagocytosis [151]. To date is known that sustained exposure to 
proinflammatory cytokines or some form of damage-associated molecular 
patterns could account for the attenuated microglial phagocytosis. That 
hypothesis is further supported by findings demonstrating that genetic 
deficiency in MRP14 increases microglial phagocytosis of Aβ [152]. Several 
surface receptors have been shown to mediate phagocytic clearance of Aβ, 
including TLR2, TLR4, TLR6, CD14 and CD36 [153]. A role for the tyrosine 
phosphatase CD45 has also been demonstrated [154]. However, the 
phagocytic uptake of Aβ maybe not only modulated by the receptors 
present on microglia but may also depend on how the Aβ aggregate is 
delivered. For example, neuronal exosomes bind Aβ and promote its 
phagocytic clearance in a phosphatidylserine-dependent way [153]. In this 
work we demostrated NLRP3 inflammasome importance in inflammatrory 
cytokines production, but the results obtained for Aβ-phagocytosis do not 
confirm our hypothesis. Anyway these results are not sufficient to establish 
whether the inflammation can be modify the Aβ clearance; FAM-Aβ is a 
protein with 5’-end-isomer [carbossifluorescein], therefore, the steric 
hindrance does not allow to generate Aβ aggregation. 
Definitely further experiments are require for better realize the mechanism 
of Aβ-phagocytosis in neuroinflammation condition. Several hypotheses 
have been formed to explain this distinctive feature of microglia surrounding 
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Aβ plaques. The first initial hypothesis suggested that microglia are 
exclusively proinflammatory in AD and have a detrimental role in the 
disease’s development [36,155]. Microglial cells lose their protective role, 
due to the persistent production and accumulation of proinflammatory 
cytokines within their microenvironment [79]. Under such conditions, 
microglial cells become hypersensitive and play a detrimental role through 
the excessive continuous production and secretion of proinflammatory and 
neurotoxic molecules [79]. Some studies indeed reported the regression of 
AD pathogenic features following non-steroidal anti-inflammatory drug 
treatment [156]. Identifying NLRP3 inflammasome as main responsible for 
the production of inflammatory cytokines both in central and peripheral level 
it can be useful certainly as future pharmacological target for the treatment 
of neurodegererative diseases, specially in AD.  
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5. CONCLUSIONS 
NLRP3 up regulation in mice or human microglia cell line or in brain of AD 
patients has been previously reported [101, 102, 157], these are 
nevertheless the first data showing NLRP3 and NLRP1 inflammasome 
activation in Aβ stimulated peripheral monocyte of individuals with a 
diagnosis of AD. Migration of these cells across the blood-brain barrier 
would likely be an important factor in the neuroinflammation that 
accompanies Alzheimer’s disease. The first results on mice primary 
microglia confirm the importance of NLRP3-inflammasome in CNS for pro-
inflammatory cytokines production. Very recent results showed that 
nucleoside reverse transcriptase inhibitors, including stavudine, inhibit the 
activation of the inflammasome [158]. If neuroinflammation is deleterious in 
AD, these drugs could be an interesting tool in the treatment of this 
disease.  
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FIGURES AND TABLES 
 
 
   AD         Predispoding factors    Onset-age   Incidence 
Familial APP and PS mutation Early < 65 age <5% 
Sporadic Elderly, physiological 
and environmental 
factors risk, ApoE4, 
Down syndrome 
Late, > 65 age 
and most 
common after 
age 80 
> 95% 
Table 1. Main differences between familial and sporadic AD 
 
Age The main risk factor 5% of the subjects 60-75 years 
<20% subjects over 80 years 
Sex Greater susceptibility for 
women than men 
2:1 ratio 
Genetic factors Mutations responsible for 
the FAD.  
ApoE ε4 [especially 
homozygous];  
Family history of dementia 
<5% 
44% of AD cases 
In 40-50% of patients with AD no 
familial incidence  
Enviroment Alcohol- smock- diet-  
   
Table2. Risk factors for AD 
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Genetic Markers ApoE ε4 
 
APP 
PS 1, 2 
located on chromosome 19; 50% 
of cases of late-onset AD is homo- 
or heterozygous for this character 
 located on chromosome 21; 
example of familial AD; early onset 
<65 years 
localized on chromosome 14 and 1 
respectively; example of familial 
AD; early onset 30-40 years 
 
Biochemical 
Markers 
Specific 
 
No-Specific 
CSF Aβ1-42, p-tau and -Tau 
concentrations 
inflammatory markers and 
oxidative stress associated with 
the primary disease process 
 
Neuroimaging NMR 
 
PET  
volumetric atrophy of the 
entorhinal cortex and trans-
entorhinal, hippocampus and 
neocortex; 
A deposits and distribution on the 
AD brain; 
 
 
Table 3. Diagnostic Criteria for AD diagnosis 
 
 
 
Figure 1. Hypothetical model of the pathological processes in Alzheimer's 
disease [AD], focusing on the amyloid β peptide [Aβ] cascade. 
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Dotted arrows indicate possible or secondary mechanisms affecting core 
pathological processes within the amyloid cascade. Background shades of 
gray separated by dotted lines are a schematic representation to integrate 
the progression of pathological events along with the development of the 
cognitive syndrome of AD [these thresholds are arbitrary and not 
experimentally validated, and represent the authors' point of view of the 
disease process]. Three clinical phases of the disease are defined: 
presymptomatic [or preclinical] AD may last for several years or decades 
until the overproduction and accumulation of Aβ in the brain reaches a 
critical level that triggers the amyloid cascade; in the predementia phase, 
compatible with the definition of mild cognitive impairment secondary to AD, 
early stage pathology is present in varying degrees, from mild neuronal 
dystrophy to early stage Braak pathology, according to individual resilience 
and brain reserve. Finally, in the clinically defined dementia phase, there is 
a progressive accumulation of the classical pathological hallmarks of AD 
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[that is, neuritic plaques and neurofibrillary tangles], bearing relationship 
with the progression of cognitive deficits and the magnitude of functional 
impairment. APP = amyloid precursor protein; PS1/2 = presenilin 1/2; TAU 
= microtubule-associated protein Tau [34]. 
 
 Figure 2. APP- processing. 
 
  
 
Amyloid Precursor Protein [APP], which contains Kunitz Proteinase 
Inhibitor [KPI], might be processed by alpha-secretase [ADAM10], which 
precludes formation of amyloid deposits, or by beta-secretase [BACE], 
leading to release of Abeta peptide [22].  
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Figure 3. Pathological evolution characterized by a gradual spread of 
amyloid deposits and neurofibrillary tangles, which are distributed from the 
entorhinal cortex and the limbic and neocortical area: 
 
 
Relationship between the progression of cognitive and functional symptoms 
and the neuropathological events in the transition from asymptomatic 
Alzheimer's disease [AD] to mild cognitive impairment due to AD and 
clinically manifest dementia of the AD type. 
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Figure 4. Alzheimer’s disease evolution. 
 
 
Correlation between the progression of cognitive symptoms and functional 
and neuropathological events in the transition from pre-clinical disease and 
AD [34]. 
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Figure 5. Innate immunity profile in the healthy brain. 
 
Intact blood–brain barrier [BBB] restricts entry into the brain of pathogens, 
toxins and blood-borne molecules, such as immunoglobulin, albumin, 
thrombin, plasmin, fibrin and laminin. Bone marrow-derived circulating 
monocytes are divided in two main subsets, which are the patrolling anti-
inflammatory [Ly6Clow] monocytes and the circulating proinflammatory 
[Ly6Chigh] monocytes. Ly6Clow monocytes are long-lived cells that ensure 
continuous surveillance by crawling on blood vessel lumen. 
Ly6Chigh monocytes are short-lived cells that are present in blood 
circulation. Perivascular macrophages [PM] probably arise from Ly6Clow 
monocytes and contribute to the maintenance of homeostasis of the 
perivascular space, mainly via its phagocytic activity. Quiescent microglia 
[QM] maintain a healthy brain microenvironment suitable for neurons [N], 
by continuously sensing any occurring changes via their high ramifications, 
secreting neurotrophic factors, namely brain-derived neurotrophic factor, 
and promoting neuronal remodeling and synaptic plasticity. 
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Figure 6. Innate immune responses in the Alzheimer’s disease brain. 
 
Age-induced cerebrovascular dysfunction induces deregulation of tight 
junction protein expression, which compromises the integrity of the blood–
brain barrier [BBB]. A compromised BBB promotes the entry of blood-borne 
molecules within the perivascular space and brain parenchyma. Patrolling 
[Ly6Clow] monocytes are mobilized by inflammatory cues triggered by 
vascular amyloid-beta [Aβ] microaggregates, contributing to their 
phagocytosis. Circulating proinflammatory [Ly6Chigh] monocytes are also 
mobilized by brain-derived inflammatory cues, adhere to brain endothelium 
and consequently infiltrate brain parenchyma. Aβ-induced inflammatory 
conditions promote the differentiation of Ly6Chigh monocytes into bone 
marrow-derived macrophages [BMDM] that exhibit enhanced Aβ 
phagocytic activity. Perivascular macrophages [PM] could contribute to 
parenchymal Aβ deposit elimination via an efficient Aβ species clearance at 
the BBB. In an Aβ-induced inflammatory microenvironment, neurons [N] 
become stressed leading to their dysfunction and ultimately their death. 
Taken together, the presence of Aβ plaques, soluble Aβ species, 
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proinflammatory molecules and blood-borne molecules constitute a 
stressful microenvironment that activates the quiescent microglia [QM]. 
Amoeboid activated microglial cells can adopt two main phenotypes that 
coexist in Alzheimer's disease brain: M1 classically activated microglia 
[AM1] and M2 alternatively activated microglia [AM2]. The switch between 
these two extreme phenotypes is influenced by age and disease 
progression. The AM1 phenotype is involved in Aβ phagocytosis and 
proinflammatory actions, such as secretion of cytokines/chemokines within 
the brain parenchyma. The AM2 phenotype is also involved in Aβ 
phagocytosis, but in contrast they have anti-inflammatory actions, including 
damaged tissue repair and remodeling, and cytokine/chemokine 
production. EC, endothelial cells. 
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Figure 7. TLR4 signaling.  
 
 
 
The lipopolysaccharide [LPS] of Gram negative bacteria is a well-known 
inducer of the innate immune response. Toll-like receptor [TLR] 4 and 
myeloid differentiation factor 2 [MD-2] form a heterodimer that recognizes a 
common 'pattern' in structurally diverse LPS molecules. Based on the 
signaling adaptors, TLR signaling can be classified into two major 
pathways: the MyD88- and TRIF-dependent pathways. TLR3 is the only 
TLR that exclusively signals through TRIF [IFN-production], whereas TLR4 
signals through both TRIF and MyD88 [73].  
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Figure 8. Nod1,2 receptors structure. 
 
 
 NLRs contain 3 domains: central NACHT [or NOD] domain, which is 
common to all NLRs, most of NLRs have also c-terminal leucine-rich repeat 
[LRR] and variable N-terminal interaction domain. NACHT domain 
mediates ATP-dependent self-oligomerization and LRR senses the 
presence of ligand. N-terminal domain is responsible for homotypic protein-
protein interaction and it can consist of caspase recruitment domain 
[CARD] or pyrin domain [PYD] [74]. 
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Figure 9. Inflammasome structure. 
 
 
Caspase-1 is activated within the inflammasome multiprotein complex 
through interaction with ASC [apoptosis-associated speck-like protein 
containing a carboxy-terminal CARD], a bipartite adapter protein 
that bridges NLRs and caspase-1 [74]. 
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Figure 10. ASC-dependent and independent inflammasome activation. The 
pathogenic role of the inflammasome in neurodegenerative diseases [76].  
 
 
Amyloid-β is known to trigger the activation of NLRP3. The exact trigger for 
NLRP1 in AD is not known but it may possible that potassium effluxes 
which trigger NLRP1 [as well as NLRP3] could occur during AD 
pathogenesis and in the process trigger NLRP1 activation. Recently it was 
suggested that palmitate, a saturated fatty acid, may play a role in 
activating NLRC4 during AD. These potential triggers may possibly activate 
NLRP3, NLRP1 and NLRC4 during AD but have yet to be confirmed 
[dashed lines]. NLRC4 can associate with pro-caspase-1. NLRP1 and 
NLRP3 associate with the adaptor protein ASC. ASC initiates the cleavage 
of pro-caspase-1 into the mature form of caspase-1, which cleaves pro-IL-
1β and pro-IL-18 into their mature forms of IL-1β and IL-18 which have 
been implicated in the pathogenesis of Alzheimer’s disease [76].  
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Figure 11. Inflammasome activation-pathway. 
.  
 
Two-signal model of innate immunity. TLRs and NLRs cooperate to 
orchestrate the innate immune response to injury. Activation of TLRs [via 
DAMPs released from CNS injury] leads to nuclear translocation of NFκB 
and transcription of pro-inflammatory cytokines, such as pro-IL-1β. 
Activation of NLRs [via a second signal] triggers inflammasome formation, 
caspase-1 activation, and cleavage of pro-IL-1β into its active form [79]. 
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Inflammasomes 
AIM2: AIM2, CASP1 [ICE], PYCARD [TMS1, 
ASC]. IPAF: CASP1 [ICE], NAIP [BIRC1], 
NLRC4 [IPAF], PYCARD [TMS1, ASC]. 
NLRP1: CASP1 [ICE], CASP5, NLRP1. 
NLRP3: CASP1 [ICE], NLRP3, PYCARD 
[TMS1, ASC].  
 
Negative Regulation of Inflammasomes 
BCL2, BCL2L1 [BCLXL], CARD18 [ICEBERG], 
CD40LG [TNFSF5], CTSB, HSP90AA1, 
HSP90AB1 [HSPCB], HSP90B1 [TRA1], 
MEFV, PSTPIP1, PYDC1 [POP1], SUGT1, 
TNF, TNFSF11 [RANKL], TNFSF14, TNFSF4 
[OX40L].  
 
Signaling Downstream of Inflammasomes 
IFNG, IL12A, IL12B, IL18, IL1B, IL33, IRAK1, 
IRF1, MYD88, P2RX7, PANX1, PTGS2 
[COX2], MOK, RIPK2, TIRAP, TXNIP. MYD88, 
P2RX7, PANX1, PTGS2 [COX2], MOK, 
RIPK2, TIRAP, TXNIP 
 
NOD-Like Receptors 
CIITA, NAIP [BIRC1], NLRC4 [IPAF], NLRC5, 
NLRP1, NLRP12 [NALP12], NLRP3, NLRP4, 
NLRP5, NLRP6, NLRP9, NLRX1, NOD1 
[CARD4], NOD2 
 
 
Signaling Downstream of NOD-Like Receptors 
BIRC2 [c-IAP1], BIRC3 [c-IAP2], CARD6, 
CASP8 [FLICE], CCL2 [MCP-1], CCL5 
[RANTES], CCL7 [MCP-3], CFLAR [Casper], 
CHUK [IKKα], CXCL1 [GRO1, GROa, SCYB1], 
CXCL2 [GRO2, GROb, SCYB2], FADD, 
IFNB1, IKBKB [IKKβ], IKBKG, IL6, IRF1, IRF2, 
MAP3K7 [TAK1], MAPK1 [ERK2], MAPK11 
[p38Beta], MAPK12 [P38GAMMA], MAPK13 
[p38delta], MAPK3 [ERK1], MAPK8 [JNK1], 
MAPK9 [JNK2], NFKB1, NFKBIA [IκBα, 
MAD3], NFKBIB [TRIP9], PEA15, RELA, 
RIPK2, SUGT1, TAB1 [MAP3K7IP1], 
Pro-Inflammatory Caspases CASP1 [ICE], CASP5. 
 
Table 4 : 84 genes involved in the Inflammasome pathway activation. 
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Figure 12. Messenger RNA expression levels of genes within the 
inflammasome pathway. 
Expression of 84 genes involved in the inflammasome pathway assessed 
by real-time quantitative RT-PCR-array in monocytes of individuals with a 
diagnosis of either severe Alzheimer’s disease [AD], moderate Alzheimer’s 
disease [MILD] or Mild Cognitive Impairment [MCI] and of age- and sex-
matched Healthy Controls [HC]. Heat maps of Log2 Fold changes are 
presented. Results obtained upon stimulating cells with LPS or Aβ1-42 alone, 
or upon LPS-priming followed by Aβ1-42 stimulation are presented. Fold-
changes >10 of the genes of importance are summarized in the Table.  
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Figure 13. mRNA expression by Real-Time PCR. 
Single Real-Time PCR results obtained in LPS and Aβ1-42 -stimulated 
monocytes of individuals with a diagnosis of either severe Alzheimer’s 
disease [AD], moderate Alzheimer’s disease [MILD] or Mild Cognitive 
Impairment [MCI] and of age- and sex-matched Healthy Controls [HC]. 
NLRP3, NLRP1, caspase 1, caspase 5 and caspase 8 are shown in panel 
A; IL1β and IL18 in panel B and IL33 and IL37 in panel C. The results are 
shown as fold-change expression from the unstimulated samples. Gene 
expression was calculated relative to GAPDH housekeeping gene. 
Summary results are shown in the bar graphs. The boxes stretch from the 
25 to the 75 percentile; the line across the boxes indicates the median 
values; the lines stretching from the boxes indicate extreme values. Outside 
values are displayed as separate points. Statistical significance is shown 
*[p<0.05],**[p<0.01].  
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Figure 14. NLRP3 expression in Monocyte by Western blot. 
NLRP3 protein expression assessed by western blotting in monocyte of 
individuals with a diagnosis of either severe Alzheimer’s disease [AD], 
moderate Alzheimer’s disease [MILD] or Mild Cognitive Impairment [MCI] 
and of age- and sex-matched Healthy Controls [HC]. The same protein 
concentration of whole-cells lysates was loaded into the gel, as confirmed 
by actin. Representative results obtained in un-stimulated or in LPS-primed 
and Aβ1-42-stimulated PBMC are presented in the upper panel. Quantitative 
evaluation [arbitrary unit] of NLRP3 expression obtained comparing band 
density in un-stimulated or in LPS-primed Aβ1-42-stimulated PBMC is shown 
in the lower panel. Mean values of 5 experiments and standard error are 
presented. 
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Figure 15. FACS analyses: co-expression of inflammasome proteins in 
CD14+ cells. 
Co-expression of inflammasome proteins in LPS-primed and Aβ1-42-
stimulated CD14+ of individuals with a diagnosis of either severe 
Alzheimer’s disease [AD], moderate Alzheimer’s disease [MILD] or Mild 
Cognitive Impairment [MCI] and of age- and sex-matched Healthy Controls 
[HC]. Two-hundred-thousand cells were acquired and gated on CD14 
expression and side scatter properties. CD14+ cells co-expressing NLRP3-
associated inflammasome components are shown in panel A; CD14+ cells 
co-expressing NLRP1-associated inflammasome components are shown in 
panel B. Summary results are shown in the bar graphs. The boxes stretch 
from the 25 to the 75 percentile; the line across the boxes indicates the 
median values; the lines stretching from the boxes indicate extreme values. 
Outside values are displayed as separate points. Statistical significance is 
shown *[p<0.05], **[p<0.01]. 
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Figure 16. Confocal microscopy: co localization of inflammasome proteins 
in CD14+ cells. 
Representative confocal fluorescence images [left part of the figure] data 
summarizing the results of 5 experiments [right part of the figure] showing 
the effect of LPS-priming and Aβ1-42-stimulation on the co-localization 
between NLRP3 and ASC [Upper panels] and of NLRP1 and Caspase 1 
[lower panels]. Monocytes of individuals with a diagnosis of either severe 
Alzheimer’s disease [AD], moderate Alzheimer’s disease [MILD] or Mild 
Cognitive Impairment [MCI] and of age- and sex-matched Healthy Controls 
[HC] are shown. Summary results of PCC [Pearson co localization 
efficiency] are presented in the bar graphs. The boxes stretch from the 25 
to the 75 percentile; the line across the boxes indicates the median values; 
the lines stretching from the boxes indicate extreme values. Outside values 
are displayed as separate points. Statistical significance is shown *[p<0.05], 
**[p<0.01]. 
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Table 5. Co-localization coefficient of inflammasome proteins.  
Pearson’s co-localization coefficient [PCC] of NLRP1 and NLRP3 with 
ASC, caspase-1, caspase-5 and caspase-8, in LPS-primed and Aβ1-42-
stimulated CD14+ monocyte of patients with a diagnosis of either severe or 
moderate [MILD] Alzheimer’s Disease [AD] and mild cognitive impairment 
[MCI]. Result obtained in and in age-and sex-matched healthy controls [HC] 
are also shown. Index reference values: PC range= -1 and +1. 
PCC severe AD  MILD AD MCI HC 
NLRP1+ ASC+ 
0.8
*° 
[0.7-0.82] 
0.8 §^ 
[0.7-0.82] 
0.5*§ 
[0.3-0.6] 
0.4
°^ 
[0.3-0.5]
 
NLRP1+ 
CASPASE-1+ 
0.6 
[0.4-0.7] 
0.8  
[0.7-0.84] 
0.6 
[0.4-0.65] 
0.5 
[0.5-0.7] 
NLRP1+ 
CASPASE-5+ 
0.7
#*° 
[0.5-0.8]
 
0.4
# 
[0.23-0.5] 
0.3
* 
[0.1-0.32] 
0.3
° 
[0.2-0.5] 
NLRP3+ ASC+ 
0.8
*° 
[0.6-0.82]
 
0.8 §
^ 
[0.7-0.82] 
0.6
*§ 
[0.5-0.7] 
0.5
°^ 
[0.4-0.6] 
NLRP3+ 
CASPASE-1+ 
0.9
#*° 
[0.8-0.9] 
0.8
#§^ 
[0.5-0.8] 
0.5
*§ 
[0.4-0.56] 
0.3
°^ 
[0.3-0.4] 
NLRP3+ 
CASPASE-8+ 
0.8
*° 
[0.7-0.85] 
0.6  
[0.5-0.72] 
0.5
* 
[0.3-0.55] 
0.5
° 
[0.3-0.6] 
Median values, interquartile range and statistical significances are presented [p<0.05]  
* AD vs. MCI; 
# 
AD vs. MILD AD; ° AD vs. HC; 
§
 MILD AD vs. MCI; 
^
 MILD AD vs. HC. 
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Figure 17. IL1β, IL18, IL33 and IL37 production. 
IL1β, [panel A], IL18 [panel B], IL33 [panel C] and IL37 [panel D]. 
Interleukin-1β and IL-18 production was assessed by multiplex ELISA in 
supernatants. CD14+/IL1β+, CD14+/IL33 and CD14+/IL37+ cells were 
analyzed by flow-cytometry. In both cases, LPS-primed and Aβ1-42-
stimulated monocytes of individuals with a diagnosis of either severe 
Alzheimer’s disease [AD], moderate Alzheimer’s disease [MILD] or Mild 
Cognitive Impairment [MCI] and of age- and sex-matched Healthy Controls 
[HC] were analyzed. Summary results are shown in the bar graphs. The 
boxes stretch from the 25 to the 75 percentile; the line across the boxes 
indicates the median values; the lines stretching from the boxes indicate 
extreme values. Outside values are displayed as separate points. Statistical 
significance is shown *[p<0.05], **[p<0.01]. 
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Figure 18. TNFα and IL1β release was evaluated in supernatants of WT 
and Knockout microglia cells collected after 2, 4, 6, 12, 24 hours with direct 
LPS-stimulation [A] and 1, 5, 11 hours with LPS-undirect stimulation [B]. 
Statistical differences are express between WT vs NLRP3 KO condition. 
[*=pvalue<0.05]. 
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Figure 19. Mature IL1β level was evaluated by ELISA on the supernatants 
of WT and KO cells upon inflammasome activation. Production was 
increase in the presence of ATP [1µM for 30’] and Nigericin [1.34 mM for 2 
hours] confirming that the release of IL1β depends on NLRP3-
inflammasome activation. Statistical differences are express between WT 
vs NLRP3 and ASC KO condition. [*=pvalue<0.05] 
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Figure 20. Western Blot analysis of NLRP3-inflammasome complex 
activation was performed by loading equal amount of RIPA fraction in each 
lane. LPS primed microglia [1x106/condition] were stimulate with ATP 
[1mM, 30 minutes] or Nigericin [Nig, 1.34 ųM for 2 hours]. The panel A 
represents bands for NLRP3, pro-Casp1, pro-IL1β and ASC in WT and KO 
lysate cells. The results were normalized to β-actin for total amount of 
protein loaded in the respective lane (Relative Ratio to β-actin). The panel 
B represents IL1β and Casp1 on supernatants of WT microglia.  
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Figure 21. Primary microglia WT and KO Aβ-phagocytosis was evaluated 
by Flow Cytometry analysis. The panel A represents LPS-direct stimulation 
for 2, 4, 6, 12 and 24 hours; the panel B represents the effect of indirect-
LPS stimulation after 1, 5, 11 hours. The results are express as percentage 
of FAM-Aβ positive cells [LPS 200ng/ml; FAM-Aβ 500nM/ml]. 
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Figure 22. The panel A shows vitality [7-AAD] and Aβ-phagocytosis [FAM-
Aβ-FITC] by flow cytometry analysis upon inflammasome activation 
condition; LPS-primed and ATP or Nigericin stimulated WT microglia cells 
were evaluated. The panel B represents results express as percentage of 
FAM-Aβ positive cells. 
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Figure 23. Primary Microglia cells morphology [A]; Flow cytometry Aβ-
phagocytosis on WT cells [Medium], LPS-primed and FAM-Aβ stimulation 
and FAM-Aβ alone treated microglia [Control] [B]; Immunohistochemistry of 
FAM-Aβ in microglia WT [C]. Immunostaining experiment demonstrated 
what expected from flow cytometry results; the presence of Aβ appears 
diffuse between cells and not only localized within the cell. [LPS 200 ng/ml; 
FAM-Aβ 500nM/ml]. Scale bar represents 20 Um. 
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